Document:

First Amendment to the Development and Marketing Agreement dated 11/10/2006

 Exhibit 10.39 
 Pursuant to 17 CFR 240.24b-2, confidential information has been omitted in places marked “[* * *]” and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential
Treatment Application filed with the Commission. 
 EXECUTION COPY 
  

 FIRST AMENDMENT TO THE DEVELOPMENT AND MARKETING AGREEMENT 
 This First Amendment (“Amendment”) to the Development and Marketing Agreement (“Agreement”) dated February 22, 2006, by and
between Spectrum Pharmaceuticals, Inc. (“Spectrum”) and Par Pharmaceutical, Inc. (“Par”) is entered into and is effective as of November 10, 2006 (“First Amendment Effective Date”), hereinafter referred to as
“Party” and, collectively, as “Parties.” Capitalized terms used but not defined herein shall have the meanings given them in the Agreement. 
 WHEREAS, on November 10, 2006, the Parties each hereby give their consent to Spectrum entering into, and Spectrum is entering into a Settlement Agreement, dated November 10, 2006 (the “Settlement
Agreement”), with Glaxo Group Limited (“GSK”) to settle the Sumatriptan Litigation. Pursuant to the Settlement Agreement, Spectrum received the right to sell Spectrum Generic Sumatriptan Products and GSK Supplied Products (both as
defined in the Settlement Agreement and the Supply and Distribution Agreement) in accordance with the terms of the Settlement Agreement; 
 WHEREAS, pursuant to the Settlement Agreement, Spectrum and Par hereby consent to, and GSK and Glaxo Wellcome Manufacturing PTE Limited and Par are entering into a Supply and Distribution Agreement, dated November 10, 2006 (the
“Supply and Distribution Agreement”)(the Settlement Agreement and the Supply and Distribution Agreement are collectively referred to herein as the “GSK Agreements”) pursuant to which GSK agrees to supply the GSK Supplied Products
to Par for distribution. Par agrees to purchase and distribute GSK Supplied Products on behalf of Spectrum in order to fulfill its obligations under the Agreement; 
 WHEREAS, the Parties wish the Agreement to apply only to GSK Supplied Products and the Spectrum Generic Sumatriptan Products, as defined in the GSK Agreements (collectively, the “GSK Sumatriptan
Products”); and 
 WHEREAS, the Parties wish to amend certain terms of the Agreement to reflect the Settlement Agreement and
Supply and Distribution Agreement and the elimination from the Agreement of all Products except the GSK Sumatriptan Products, among other changes, as set forth below. 
 NOW, THEREFORE, in consideration of the mutual covenants, promises and agreements set forth herein, the Parties hereby agree as follows: 
  

	 	1.	 In the event that GSK and Spectrum modify the terms of the Settlement Agreement or the Supply and Distribution Agreement in accordance with Sections 4 & 5 of
the Settlement Agreement, then Par and Spectrum shall 

 Pursuant to 17 CFR 240.24b-2, confidential information has been omitted in places marked “[*
* *]” and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application filed with the Commission. 
 EXECUTION COPY 
  

	 	 
consider whether any corresponding modifications ought to be made to the Agreement, as modified by this First Amendment, and, if so, they shall negotiate
such modifications in good faith. The Parties acknowledge that, due to reasons stated in the Settlement Agreement both the Settlement Agreement and the Supply and Distribution Agreement may be terminated. 

  

	 	2.	Spectrum hereby assigns and Par hereby assumes the commercial and marketing obligations of Spectrum under the Settlement Agreement. Any material breach of the Supply and
Distribution Agreement or the Settlement Agreement by Par shall be considered a material breach of the Agreement, subject to cure under the Agreement. To the extent there is any conflict between Par’s obligations under the Agreement and the
Supply and Distribution Agreement and the Settlement Agreement solely with regard to the GSK Sumatriptan Products, the terms of the Supply and Distribution Agreement and the Settlement Agreement, respectively, shall apply. Additionally, while
Spectrum will remain free to cure any breach under the Supply and Distribution Agreement pursuant to Section 7.2(c) thereof, Spectrum agrees that it will not step in and assume all of Par’s rights and obligations thereunder, without first
giving Par a full and fair opportunity to cure thereunder. 

  

	 	3.	As long as the Settlement Agreement and the Supply and Distribution Agreement are effective, then Spectrum shall not be responsible for any development obligations under
Section 2 or any regulatory obligations under Section 3 for any of the GSK Supplied Products. Spectrum’s obligations, however, with respect to the [* * *] Products set forth on Schedule 1.33 shall continue. In the event
that, the Supply and Distribution Agreement terminates or expires then (1) Spectrum’s obligations under the Agreement with respect to the [* * *] Product set forth on Schedule 1.33 shall promptly resume and (2) with respect
to [* * *] and the [* * *] presentations of injectable sumatriptan products, the Parties shall discuss in good faith whether and how best to proceed, if at all. 

  

	 	4.	Within thirty (30) days of the First Amendment Effective Date, Par shall make a non-refundable, non-creditable payment to Spectrum of five million dollars ($5,000,000) in
consideration for Spectrum receiving tentative approval, amending the Agreement and entering into this Amendment. Par acknowledges that Spectrum has no future obligations or performance contingencies associated with this payment.

  

	 	5.	 Section 1.10 shall be amended to read 

 Pursuant to 17 CFR 240.24b-2, confidential information has been omitted in places marked “[*
* *]” and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application filed with the Commission. 
 EXECUTION COPY 
  

	 	 
“Competing Product” means any Drug Product that is an injectable [* * *] form of sumatriptan, excluding the Products under this Agreement
as made and sold per the terms of this Agreement and the GSK Supplied Products under the terms of the GSK Agreements. 

  

	 	6.	Section 1.16 shall be deleted in its entirety. 

  

	 	7.	Section 1.18 shall be deleted in its entirety. 

  

	 	8.	Section 1.19 shall be deleted in its entirety. 

  

	 	9.	Section 1.20 shall be deleted in its entirety. 

  

	 	10.	Section 1.22 shall be deleted in its entirety. 

  

	 	11.	Section 1.33 of the Agreement shall be amended in its entirety to read: 

 “‘Products’ means GSK Sumatriptan Products and the products listed on Schedule 1.33, except for the injectable [* * *] presentation listed on Schedule 1.33 unless the Settlement Agreement and
the Supply and Distribution Agreement are terminated in which case the injectable [* * *] presentation will be included.’” 
  

	 	12.	In Section 1.36, “and NDAs” shall be added after “ANDAs”. 

  

	 	13.	Section 1.37 shall be deleted in its entirety. Any reference in the Agreement to “Sumatriptan Products” shall be replaced with “Products.”

  

	 	14.	Section 1.38 shall be deleted in its entirety and replaced by the following: 

 “Territory” shall mean the United States of America (including the Commonwealth of Puerto Rico) its possessions and territories and U.S. military or U.S. government installations that are under the purview
of the FDA. 
  

	 	15.	Add a new Section 1.42: 

 “Product Claims”
shall have the meaning given such term in the Supply and Distribution Agreement. 
  

	 	16.	Section 2.4 shall be deleted in its entirety. 

 Pursuant to 17 CFR 240.24b-2, confidential information has been omitted in places marked “[*
* *]” and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application filed with the Commission. 
 EXECUTION COPY 
  

	 	17.	Section 4.2.7 shall be deleted in its entirety. 

  

	 	18.	Section 4.2.8 shall be deleted in its entirety. 

  

	 	19.	Section 5.1 shall be deleted in its entirety and replaced by the following: 

 License Grant. Spectrum hereby grants to Par an exclusive (even as to Spectrum) royalty free (other than as set forth in Article 7), irrevocable (subject to Article 14) license to market, promote, distribute,
sell and have sold the Products in the Territory. To the extent permitted by the Supply and Distribution Agreement, the foregoing license shall include the right for Par to grant sublicenses and appoint sub-contractors to market, distribute and sell
the Products within the Territory on Par’s behalf. 
  

	 	20.	Section 5.2.2 shall be deleted in its entirety. 

  

	 	21.	In Section 5.2.3 the following shall be added to the end of the last sentence: “and in accordance with Section 4.2(e) of the Supply and Distribution Agreement.”

  

	 	22.	In Section 5.3 the following shall be added to the end of the last sentence: 

 Notwithstanding the foregoing, where applicable, the Commercial Launch of the Product, and Par’s obligations in regard to such Commercial Launch, shall be subject to the applicable provisions set forth in the
Supply and Distribution Agreement and the Settlement Agreement. 
  

	 	23.	In Section 5.6 the following shall be added to the end of the last sentence: 

 Notwithstanding the foregoing, recalls of the Product, and Par’s obligations in regard to such Recalls, shall be subject to Section 5.8(b) of the Supply and Distribution Agreement, as applicable. Without
limiting the foregoing, Par shall promptly notify Spectrum of any Recalls which it may be necessary to conduct and consult with Spectrum as to how best to proceed. 
  

	 	24.	In Section 6.1, the reference to “contractual restrictions regarding Competing Product competitive activities,” shall not apply to the GSK Agreements.

  

	 	25.	Section 6.4 shall be deleted and replaced in its entirety by the following: 

 Par shall permit Spectrum’s quality assurance representatives to inspect the manufacturing, distribution and storage facilities and all books and records of 

 Pursuant to 17 CFR 240.24b-2, confidential information has been omitted in places marked “[*
* *]” and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application filed with the Commission. 
 EXECUTION COPY 
  

 
Par relating to the production of the Product at all times upon thirty (30) days prior written notice, during normal business hours and on a
confidential basis; provided, however, that such inspections shall be limited to twice annually in the absence of a breach of this Agreement by Par. The foregoing obligation shall not apply with regard to GSK or GSK Supplied Products. Par will use
commercially reasonable efforts to include Spectrum in any inspections of GSK facilities in connection with GSK Supplied Product, and if Par is unable to do so will provide a written report regarding the same to Spectrum. 
  

	 	26.	In Section 6.6.1.3, the following text shall be added: “or applicable NDA” after “the applicable ANDA”. Additionally, the representations in
Section 6.6.1 shall not apply with respect to GSK Supplied Product. 

  

	 	27.	Section 7.1.1 shall be deleted in its entirety. 

  

	 	28.	Section 7.2 of the Agreement shall be deleted in its entirety. 

  

	 	29.	Section 7.4 of the Agreement shall be deleted in its entirety. 

  

	 	30.	Section 8.1 of the Agreement shall be revised to read: 

 Any intellectual property rights (including patents, patent applications, know-how, trade secrets, copyrights, trade dress, housemarks and trademarks) owned by either Party or its Affiliates prior to the Effective Date shall remain solely
owned by such Party (or its Affiliates, as applicable). Each of the Parties shall not during the Term, or at any time thereafter, represent or assert that it is the owner of any such intellectual property rights of the other Party (or its
Affiliates), whether or not such rights are registered. The Parties do not contemplate that any development activities will be performed under this Agreement, but in the event that any such activities should be conducted under this Agreement the
intellectual property laws of the United States and the State of New York will govern the allocation of intellectual property rights among the Parties in any developments resulting from such activities. 
  

	 	31.	A new Section 10.5 shall be added as follows: 

 “Notwithstanding the foregoing, Par shall have the right to disclose Confidential Information of Spectrum that it acquires under this Agreement to GSK, but only to the extent necessary for Par to comply with its obligations under the
Supply and Distribution Agreement and only after receipt of prior written consent from Spectrum.” 

 Pursuant to 17 CFR 240.24b-2, confidential information has been omitted in places marked “[*
* *]” and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application filed with the Commission. 
 EXECUTION COPY 
  

	 	32.	In Section 11.1.5 the following text shall be added: 

 “, except as may be set forth in the Settlement Agreement or Supply and Distribution Agreement” after “to any royalties or fees”. 
  

	 	33.	Section 12.1 shall be amended as follows: 

 First,
move “, (i)” after “arising out of.” 
 Second, after “obligation of Par under this Agreement” add “or
under the Supply and Distribution Agreement” 
 Third, strike “or” before “(iii).” 
 Fourth, add at the end of the paragraph: “or (iv) any Product Claims (as defined in the Supply and Distribution Agreement).” 
  

	 	34.	The Agreement is hereby amended to add a new Section 12.6 which shall read as follows: 

 12.6 “Indemnification Obligation for GSK Supplied Product.” With respect to any Product Claims or claims for indemnification by GSK under the
Supply and Distribution Agreement, the obligation in respect of such claims shall [* * *]. 
  

	 	35.	The last sentence of Section 14.4 shall be deleted . 

  

	 	36.	Section 14.5 shall be deleted in its entirety. 

  

	 	37.	Section 14.6 shall be deleted in its entirety. 

  

	 	38.	Section 14.8 shall be deleted in its entirety. 

  

	 	39.	Section 16.4 of the Agreement shall be amended by adding the following sentence to the end of the paragraph: 

 “Notwithstanding the foregoing, Spectrum may assign, sell, transfer or otherwise convey its right to receive its share of the Net
Profit under Section 7.1 of this Agreement to a Third Party.” 
  

	 	40.	In Section 16.13 the following text shall be added: 

 “, and the Settlement Agreement and the Supply and Distribution Agreement,” after “Confidentiality Agreement”. 

 Pursuant to 17 CFR 240.24b-2, confidential information has been omitted in places marked “[*
* *]” and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application filed with the Commission. 
 EXECUTION COPY 
  

	 	41.	A new Section 16.16 shall be added: 

 [***]. In
the event that there is a [***], Spectrum may [***], all [***] from the date [***] accordance with an [***] mutually agreed to by and among [***] shall also include [***]. 
  

	 	42.	Schedule 1.18 shall be deleted in its entirety. 

  

	 	43.	Schedule 1.19 shall be deleted in its entirety. 

  

	 	44.	Schedule 1.20 shall be deleted in its entirety. 

  

	 	45.	Add Schedule 1.33 as attached. 

  

	 	46.	Schedule 1.37 shall be deleted in its entirety. 

  

	 	47.	Schedule 7.21 shall be deleted in its entirety. 

  

	 	48.	Schedule 11.1.5 shall be deleted in its entirety. 

  

	 	49.	Any references in the Agreement to the above deleted Schedules shall be deleted. 

  

	 	50.	A new Section 7.6 shall be added to read as follows: 

 GSK Agreement: In the event that Par recovers any damages, including [* * *], under the Supply and Distribution Agreement Par shall pay Spectrum [* * *] percent ([* * *]%) of such damages within
[* * *] ([* * *]) days after recovering them. 

 Pursuant to 17 CFR 240.24b-2, confidential information has been omitted in places marked “[*
* *]” and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application filed with the Commission. 
 EXECUTION COPY 
  

 All amounts paid to GSK under the GSK agreements shall be included in the calculation of Net
Profits. 
 51. Consistent with the representations, warranties and covenants made in this Amendment, the Settlement Agreement, the
Supply & Distribution Agreement and the Stipulation of Dismissal, as of the Execution Date, Spectrum and each of its respective predecessors, successors, parents, subsidiaries, Affiliates, divisions, general partners, limited partners, and
assigns (collectively, the “Spectrum Releasees”), fully, finally and forever release, relinquish, acquit, and discharge Par and each of its respective predecessors, successors, parents, subsidiaries, Affiliates, divisions, general
partners, limited partners, and assigns, (collectively, the “Par Releasees”) of and from, and covenant not to sue, not to assign to any other entity a right to sue, and not to authorize any other entity to sue, any Par Releasee for, any
and all claims, counterclaims, defenses, demands, causes of action, suits, damages, debts, liabilities, obligations, rights, and set-offs of any and all kind or description whatsoever, including costs, expenses, and attorneys’ fees
(collectively, “Losses”), known or unknown, suspected or unsuspected, asserted or unasserted, in law or equity, on which no judgment has yet been rendered, from the beginning of the world to the Execution Date that could have been, are or
could be asserted in connection with the obligations of the parties under the Agreement through the date of this Amendment, and in connection with the entering into of the GSK Agreements by either Party or that arise out of any claim, counterclaim,
affirmative defense, act, transaction, series of transactions, fact, omission, or matter that could have been, is or was the subject matter of the District Court Case (collectively, “Acts”). Consistent with the representations, warranties
and covenants made in this Amendment, the Settlement Agreement, the Supply & Distribution Agreement and the Stipulation of Dismissal, as of the Execution Date, Par and each of the other Par Releasees, fully, finally and forever release,
relinquish, acquit, and discharge the Spectrum Releasees of and from, and covenant not to sue, not to assign to any other entity a right to sue, and not to authorize any other entity to sue, any Spectrum Releasee for, any and all Losses, known or
unknown, suspected or unsuspected, asserted or unasserted, in law or equity, on which no judgment has yet been rendered, from the beginning of the world to the Execution Date that could have been, are or were asserted in the District Court Case, or
that arise out of any Acts. 
 Except as provided herein, all other terms and conditions of the Agreement shall remain in full force and
effect. 
 [Signature page to follow] 

 Pursuant to 17 CFR 240.24b-2, confidential information has been omitted in places marked “[*
* *]” and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application filed with the Commission. 
 EXECUTION COPY 
  

 [Signature Page to First Amendment to Development and Marketing Agreement] 

IN WITNESS WHEREOF, the Parties hereto have executed this First Amendment to the Development and Marketing Agreement to be effective as of the First
Amendment Effective Date. 
 SPECTRUM PHARMACEUTICALS, INC. 
  

			
	By:	 	 /s/ Rajesh C. Shrotriya, M.D.

		
	Name:	 	 Rajesh C. Shrotriya, M.D.

		
	Title:	 	 Chairman, CEO and President

 PAR PHARMACEUTICAL, INC. 
  

			
	By:	 	 /s/ Patrick G. LePorre

		
	Name:	 	 Patrick G. LePorre

		
	Title:	 	 President and CEO

 Pursuant to 17 CFR 240.24b-2, confidential information has been omitted in places marked “[*
* *]” and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application filed with the Commission. 
 EXECUTION COPY 
  

 Schedule 1.33 
  

									
	 NDA
No.
	  	 Reference Listed Drug
	  	 Dosage Form;
 Route
	  	 Strength
	  	 Package Form

					
	 [* * *]
	  	[* * *]	  	[* * *]	  	[* * *]	  	[* * *]Supply and Distribution Agreement dated 11/10/2006

 Exhibit 10.40 
 Pursuant to 17 CFR 240.24b-2, confidential information has been omitted in places marked “[* * *]” and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential
Treatment Application filed with the Commission. 
  

 SUPPLY AND DISTRIBUTION AGREEMENT 
 among 
 GLAXO GROUP LIMITED, 
 GLAXO WELLCOME MANUFACTURING PTE LIMITED 
 and 
 PAR PHARMACEUTICAL, INC. 
 November 10, 2006 

 Pursuant to 17 CFR 240.24b-2, confidential information has been omitted in places marked “[*
* *]” and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application filed with the Commission. 
  

 SUPPLY AND DISTRIBUTION AGREEMENT 
 Table of Contents 
  

			
	 Article I - Definitions
	  	2
		
	 Article II – Effective Date
	  	8
		
	 Article III - Payments
	  	8
		
	 Article IV – Supply
	  	12
		
	 Article V - Representations, Warranties and Covenants
	  	21
		
	 Article VI - Intellectual Property and Confidential Information
	  	26
		
	 Article VII - Term And Termination
	  	29
		
	 Article VIII - Indemnification, Insurance and Dispute Resolution
	  	31
		
	 Article IX - Miscellaneous
	  	35

 Pursuant to 17 CFR 240.24b-2, confidential information has been omitted in places marked “[*
* *]” and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application filed with the Commission. 
  

 SUPPLY AND DISTRIBUTION AGREEMENT 
 Table of Exhibits, Schedules and Appendices 
  

			
	 Schedule 3.4(a)
	  	GSK Supplied Product Supply Price
		
	 Schedule 3.4(c)
	  	Form of Trading Services Agreement
		
	 Schedule 4.2(b)
	  	Form of Quality Agreement
		
	 Schedule 4.2(b)(iii)
	  	GSK Supplied Product and its Specifications
		
	 Schedule 4.2(c)
	  	GSK Supplied Product and Initial PAR Estimate
		
	 Schedule 4.2(d)
	  	Initial Quantity
		
	 Schedule 4.4
	  	Form of Pharmacovigilance Agreement
		
	 Schedule 6.3
	  	Press Release

 Pursuant to 17 CFR 240.24b-2, confidential information has been omitted in places marked “[*
* *]” and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application filed with the Commission. 
  

 SUPPLY AND DISTRIBUTION AGREEMENT 
 PREAMBLE 
 This SUPPLY
AND DISTRIBUTION AGREEMENT dated as of the 10th day of November, 2006 (the “Execution Date”) by and among Glaxo Group Limited, a company incorporated in England and Wales, having its registered office at Glaxo Wellcome House,
Berkeley Avenue, Greenford, Middlesex, England UB6 0NN, and Glaxo Wellcome Manufacturing PTE Limited, having its registered office at 1 Pioneer Sector 1, Jurong, Singapore 628413 (collectively, “GSK”), and PAR Pharmaceutical
Companies, Inc., a Delaware corporation having its office at 300 Tice Boulevard, 3rd Floor, Woodcliff Lake, NJ 07677
(“PAR”). PAR and GSK are sometimes collectively referred to herein as the “Parties” and separately as a “Party.” 
 WHEREAS, GSK and Spectrum Pharmaceuticals, Inc. (“Spectrum”) entered into that certain Settlement Agreement (as that term is hereinafter defined) on November 10, 2006; 
 WHEREAS, pursuant to such Settlement Agreement, GSK and Spectrum have agreed to enter into this Agreement under which GSK (or its Affiliate) has agreed
to supply GSK Supplied Products (as that term is hereinafter defined) to Spectrum for distribution in the Territory (as that term is hereinafter defined) upon the terms and conditions set forth herein; 
 WHEREAS, pursuant to a certain Development and Marketing Agreement dated February 22, 2006 (as amended), by and between Spectrum and PAR (the
“Marketing Agreement”), Spectrum has granted PAR a license to market, promote, distribute and sell certain pharmaceutical products on behalf of Spectrum in the United States, its territories, possessions, protectorates and the
Commonwealth of Puerto Rico, and under such Marketing Agreement, PAR is responsible for entering into any commercial supply agreement that is necessary to allow PAR to obtain adequate quantities of such pharmaceutical products; 
 WHEREAS, in order to fulfill its obligations under the Marketing Agreement PAR and its Affiliates desire to exclusively purchase certain GSK Supplied
Products for resale to its (or their) distributors and other customers for ultimate sale to consumers in the Territory, and GSK (or its Affiliate) desires to manufacture and supply the GSK Supplied Products to PAR and its Affiliates in such
Territory subject to the terms and conditions set forth in this Agreement; and 
 WHEREAS, PAR and Spectrum acknowledge and agree that PAR
shall enter into this Agreement on behalf of Spectrum pursuant to the terms and conditions of the Settlement Agreement, and that PAR shall purchase the GSK Supplied Products and market, promote, distribute and sell such GSK Supplied Products in the
Territory subject to the respective rights and obligations of PAR and Spectrum set forth in the Marketing Agreement. 
 NOW, THEREFORE, in
consideration of the mutual covenants, agreements and stipulations set forth herein, the receipt and legal sufficiency of which are hereby mutually acknowledged, the Parties hereby agree as follows: 
  

 1 

 Pursuant to 17 CFR 240.24b-2, confidential information has been omitted in places marked “[*
* *]” and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application filed with the Commission. 
  

 ARTICLE I - DEFINITIONS 
 Section 1.1 Definitions. As used in this Agreement, the following terms, whether used in the singular or plural, shall have the following
meanings: 
 “A Rated” shall mean that the product in question has been assigned an “A” rating signifying that the
FDA has classified the product as “therapeutically equivalent” to the particular product in question, applying the definition of “therapeutically equivalent” set forth in the preface to the current edition of the then current FDA
publication “Approved Drug Products With Therapeutic Equivalence Evaluations”. 
 “Affiliate” shall mean any
Person which controls, is controlled by, or is under common control with the applicable Person. For purposes of this definition, “control” shall mean: (a) in the case of corporate entities, direct or indirect ownership of at least
fifty percent (50%) of the stock or shares (or such lesser percentage which is the maximum allowed to be owned by a foreign corporation in a particular jurisdiction) entitled to vote for the election of directors, or otherwise having the power
to control or direct the affairs of such Person; and (b) in the case of non-corporate entities, direct or indirect ownership of at least 50% of the equity interest or the power to direct the management and policies of such noncorporate
entities. 
 “Agreement” shall mean this Supply and Distribution Agreement including all exhibits, schedules and appendices
attached hereto. 
 “ANDA” shall mean an Abbreviated New Drug Application as defined in the U.S. Federal Food, Drug, and
Cosmetic Act and all applicable regulations promulgated thereunder. 
 “Applicable Law” shall mean all applicable provisions
of all statutes (including the Federal Food, Drug and Cosmetic Act), laws, rules, regulations, administrative codes, ordinances, decrees, orders, decisions, guidance documents (including FDA guidance documents), injunctions, awards, judgments, and
permits and licenses of or from governmental authorities relating to the use, marketing or regulation of the subject item. 
 “Auditor” shall have the meaning set forth in Section 3.9. 
 “Business Day” shall mean any
day other than a day which is a Saturday, a Sunday or federal bank or federal government holiday in the United States or the UK. 
 “cGMP” shall mean the then-current good manufacturing practices of the FDA, as set forth in 21 C.F.R. Parts 210 and 211 and all applicable rules, regulations, guides and guidances. 
 “Calendar Quarter” shall mean each of the three (3) month periods during a calendar year starting on the first of January, April,
July and October. 
 “Claim” shall have the meaning set forth in Section 8.1(c)(i). 
 “COGS Auditor” shall have the meaning set forth in Section 7.2(e)(ii). 
 “Commercially Reasonable Efforts” shall mean with respect to a Party, efforts and diligence in accordance with business matters in the
pharmaceutical industry that are of high importance to the Party and which are consistent with the subject Party’s reasonable and sound business and legal judgment. 
  

 2 

 Pursuant to 17 CFR 240.24b-2, confidential information has been omitted in places marked “[*
* *]” and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application filed with the Commission. 
  

 “Confidential Information” shall mean any and all confidential information
regarding, related to, or associated with this Agreement as may be provided by one Party to the other including (a) the GSK Supplied Product or the Net Sales Split Reports (and all information contained therein), that is disclosed by the
Disclosing Party to the Recipient, or (b) this Agreement (including the terms and conditions hereof). Provided, however, that Confidential Information shall not include information which (i) at the time of disclosure is in the public
domain, (ii) after disclosure becomes part of the public domain, except through breach of this Agreement, (iii) the Recipient can demonstrate by reasonable proof was in its possession prior to the time of disclosure by the Disclosing Party
hereunder, and was not acquired directly or indirectly from the Disclosing Party, (iv) becomes available to Recipient free of an obligation of confidentiality from a Third Party who did not acquire such information directly or indirectly from
the Disclosing Party and who is not otherwise prohibited from disclosing such information, or (v) is independently developed by the Recipient without reference to Confidential Information disclosed by the Disclosing Party. 
 “Cost of Goods” shall mean [* * *] the applicable GSK Supplied Product in finished dosage form labeled and packaged for use by
the ultimate consumer, including, without limitation, [* * *] calculated in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) applied in a consistent manner. GSK’s methods for allocating
[* * *] shall also be consistent with GSK’s then current practices with respect to GSK products which have similar requirements to the applicable GSK Supplied Product regarding [* * *] in finished dosage form. 
 “Disclosing Party” shall have the meaning set forth in Section 6.2(a). 
 “Diverted Product Net Sales Split” shall have the meaning set forth in Section 3.1(b). 
 “Effective Date” shall have the meaning set forth in Section 2.1. 
 “Execution Date” shall be the date upon which this Agreement shall be mutually executed by authorized representatives of each Party,
which date shall be that which is set forth in the Preamble. 
 “FDA” shall mean the U.S. Food and Drug Administration, or
any successor agency thereto. 
 “Forecast” shall have the meaning set forth in Section 4.2(c)(i). 
 “Generic Equivalent” shall mean the prescription Sumatriptan injection in the [* * *] presentation for human use that is
supplied or manufactured by or for GSK (or its Affiliates) under a GSK owned or controlled NDA for sale in the United States as a generic equivalent to GSK’s Imitrex® (Sumatriptan) injection in the [* * *] presentation. For the avoidance of doubt, Generic Equivalents shall
not include any product marketed and sold under GSK’s Imitrex® trademark. 
 “Generic Injection Product” shall mean the generic form of the prescription
Sumatriptan injection [* * *] for use in humans as further detailed in the applicable Specifications set forth in Schedule 4.2(b)(iii). For the avoidance of doubt, Generic Injection Product shall not include the [* * *]
presentation or any other forms, formulations, dosages or presentations of Product, whether branded or generic; and for the further avoidance of doubt, Generic Injection Product shall not include any other forms, formulations dosages or
presentations, whether branded or generic, of GSK’s Imitrex® products or other products sold under other GSK owned or controlled trademarks. 
  

 3 

 Pursuant to 17 CFR 240.24b-2, confidential information has been omitted in places marked “[*
* *]” and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application filed with the Commission. 
  

 “Generic [* * *] Product” shall mean the generic form of the prescription
Sumatriptan injection in [* * *] presentation for use in humans as further detailed in the applicable Specifications set forth in Schedule 4.2(b). For the avoidance of doubt, Generic [* * *] Product shall not include the
[* * *] presentation (subject to Section 4.1(d)) or any other forms, formulations, dosages or presentations of Product, whether branded or generic; and for the further avoidance of doubt, Generic [* * *] Product shall not
include any other forms, formulations dosages or presentations, whether branded or generic, of GSK’s Imitrex® products or other products sold under other GSK owned or controlled trademarks. Sumatriptan 
 “Generic Injection Net Sales Split” shall have the meaning set forth in Section 3.1. 
 “GSK” shall have the meaning set forth in the Preamble. 
 “GSK Claim” shall have the meaning set
forth in Section 8.1(b). 
 “GSK Losses” shall have the meaning set forth in Section 8.1(b). 
 “GSK Party” shall have the meaning set forth in Section 8.1(b). 
 “GSK Supplied Product” shall mean the Generic Injection Product and the Generic
[* * *] Product for human use supplied to PAR (and its Affiliates) by GSK (and its Affiliates) pursuant to the provisions of this Agreement. For the avoidance of doubt, GSK Supplied Product shall not include any other forms, formulations,
dosages or presentations of Product, whether branded or generic, including any other forms, formulations, dosages or presentations, whether branded or generic, of Imitrex® except that it may include the [* * *] presentation as provided in Section 4.1(d). 
 “Initial Quantity” shall have the meaning set forth in Section 4.2(d)(i). 
 “Launch Date” shall mean shall mean [***] 
 “Labels or Labeling” shall mean all labels and other written, printed or graphic matter upon (a) the GSK Supplied Product or any container, carton or wrapper or other packaging utilized with the
GSK Supplied Product or (b) any written material accompanying the GSK Supplied Product, including, without limitation, package inserts or outserts or medical information guides. 
 “NDA” shall mean a New Drug Application as defined in the U.S. Federal Food, Drug, and Cosmetic Act and all applicable regulations
promulgated thereunder. 
 “NDC” shall mean a National Drug Code. 
 “Net Sales” shall mean the aggregate gross sales (“Gross Sales”) amount invoiced for GSK Supplied Product by PAR (and
its Affiliates) to its (or their) distributors and customers (for purposes of this definition, collectively, “customer”) less the following deductions relating to such sales to the extent 

  

 4 

 Pursuant to 17 CFR 240.24b-2, confidential information has been omitted in places marked “[*
* *]” and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application filed with the Commission. 
  

 
such deductions are consistent with the normal practice in the pharmaceutical products industry and are related solely to GSK Supplied Products: 

(a) [***]; 
 (b) [***]; 
 (c) [***]; 
 (d) [***]; 
 (e) [***]; 
 (f) [***]; 
 (g) [***]; and 
 (h) [***]. 
 The foregoing deductions from Gross Sales shall only be deducted once and only to the extent not otherwise deducted from Gross Sales. PAR shall be
responsible for payment of rebates or other price reductions required pursuant to Applicable Law to be made by PAR (or its Affiliates) based on its sales of GSK Supplied Product to any governmental or regulatory authority in respect of any state or
federal Medicare, Medicaid or similar programs. 
 In the event that PAR (or its Affiliates) sells GSK Supplied Product as part of a bundle
or group sale with other products not covered by this Agreement, and PAR (or its Affiliates) provide a discount, allowance or rebate to the purchaser of such products based on the invoiced prices for all products sold, such discount must be
allocated pro-rata based on the selling prices of such products before taking into account the discount, allowance or rebate on GSK Supplied Product provided as part of such bundle. 
 In the event that a GSK Supplied Product is sold or otherwise commercially exploited by PAR (or its Affiliates) in a manner such that the above means of
calculating Net Sales is not possible or otherwise is inappropriate, the Parties agree to negotiate in good faith a reasonable mechanism for fairly calculating the “Net Sales” resulting from such sales or other commercial exploitation. Net
Sales shall be determined in accordance with the accrual method of accounting in accordance with USA generally accepted accounting principles (“GAAP”) applied in a consistent manner. 
  

 5 

 Pursuant to 17 CFR 240.24b-2, confidential information has been omitted in places marked “[*
* *]” and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application filed with the Commission. 
  

 “Net Sales Split” shall mean, collectively, the Generic Injection Net Sales Split
and the Diverted Product Net Sales Split. 
 “Net Sales Split Report” shall have the meaning set forth in Section 3.3.

 “OTC” shall mean the subject pharmaceutical drug is available for human use without requiring a prescription, i.e., an
‘over-the-counter’ pharmaceutical drug for human use. 
 “PAR” shall have the meaning set forth in the Preamble.

 “PAR Claim” shall have the meaning set forth in Section 8.1(a). 
 “PAR Losses” shall have the meaning set forth in Section 8.1(a). 
 “PAR Party” shall have the meaning set forth in Section 8.1(a). 
 “Party or Parties” shall have the meaning set forth in the Preamble. 
 “Person” shall mean any natural person, corporation, unincorporated organization, partnership, association, joint stock company, joint
venture, limited liability company, trust or government, or any agency or political subdivision of any government, or any other entity. 
 “Pharmacovigilance Agreement” shall have the meaning set forth in Section 4.4. 
 “Prime
Rate” shall mean the rate of interest that Citibank N.A. lists as its prime lending rate on the last day of the applicable Calendar Quarter, or if such rate is not available, the prime lending rate listed in the New York City, USA version
of The Wall Street Journal on the last day of the applicable Calendar Quarter. 
 “Products” shall mean all prescription
pharmaceutical drug products in injection form, including all dosages and presentations thereof, for human use, consisting of or containing Sumatriptan. Product shall include all Generic Injection Products, Generic [* * *] Products and GSK
Supplied Products. For the avoidance of doubt, PAR shall only have the rights to GSK Supplied Product that are explicitly set forth herein. 
 “Product Action” shall have the meaning set forth in Section 5.8(b). 
 “Product Claims”
shall mean [***]. 
 “Promotional Materials” shall have the meaning set forth in Section 4.5. 
 “Quality Agreement” shall have the meaning set forth in Section 4.2(b). 
 “Reasonable Quantity Requirements” shall mean, subject to Section 4.2(d)(ii), such quantity of Generic Injection Product and
Generic [* * *] Product, that (a) PAR reasonably believes it requires for sale in the Territory pursuant to the immediate previously provided forecast consistent with reasonable market and demand information for Generic Injection
Product and Generic [* * *] Product, and (b) is not in excess of the applicable non-binding forecast previously provided to GSK. 
  

 6 

 Pursuant to 17 CFR 240.24b-2, confidential information has been omitted in places marked “[*
* *]” and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application filed with the Commission. 
  

 “Recipient” shall have the meaning set forth in Section 6.2(a). 
 “Settlement Agreement” shall mean the Settlement Agreement, entered into by and between GSK and Spectrum, which is dated as of
November 10, 2006, relating to that certain cases captioned GSK v. Spectrum, Civil Action No. 05-99-GMS and GSK v. Spectrum, Civil Action No. 06-0558-GMS in the United States District Court for the District of Delaware. 
 “Sumatriptan” shall mean sumatriptan succinate, a selective 5-hydroxytryptamine (5-HT1) receptor subtype agonist chemically designated
as “3-[2-(dimethylamino)ethyl]-N-methyl-indole-5-methanesulfonamide succinate (1:1)”. 
 “Supply Price” shall have
the meaning set forth in Section 3.4(a). 
 “Supply Term” shall mean the period between the Launch Date and the Supply
Termination Date. 
 “Supply Termination Date” shall mean the earlier of: (i) the date that is [* * *]
([* * *]) years after the Launch Date, as such date may be extended pursuant to Section 4.1(b); or (ii) the date upon which this Agreement terminates for any reason. 
 “Term” shall have the meaning set forth in Section 7.1. 
 “Territory” shall mean the United States of America (including the Commonwealth of Puerto Rico) its possessions and territories and U.S.
military or U.S. government installations that are under the purview of the FDA. 
 “Third Party” shall mean any Person
other than PAR or GSK, or an Affiliate of either of them. 
 “[***]” shall mean, [***], based on [***] under which all [***]
for each of the [***]. By way of example, if the [***] has occurred for the [* * *] apply only to the [* * *] and shall not mean the [* * *]. 
 “Third Party Generic Sumatriptan Product” shall mean any Third Party’s prescription generic Sumatriptan injection (e.g., in any of
the [* * *]) product for human use that has received Final Approval from the FDA; and is A-Rated to the [* * *] approved under GSK’s NDA [* * *]; provided that such Third 

  

 7 

 Pursuant to 17 CFR 240.24b-2, confidential information has been omitted in places marked “[*
* *]” and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application filed with the Commission. 
  

 
Party Generic Sumatriptan Product is not licensed, distributed or sold in the United States by (or with) PAR (or their respective Affiliates) or made from a
finished or semi-finished dosage form formulated for use in the United States with direct or indirect support provided knowingly by PAR (or their respective Affiliates). For the avoidance of doubt, Third Party Generic Sumatriptan Product shall not
include GSK Supplied Product or any Sumatriptan injection product sold under GSK’s Imitrex® trademark. 
 “Trading Services Agreement” shall have the
meaning set forth in Section 3.4(c). 
 “Trigger Date” shall mean, [***]: 
 [***] 
 Section 1.2 The
word “including” or any variation thereof means “including without limitation” or any variation thereof and shall not be construed to limit any general statement which it follows to the specific or similar items or matters
immediately following it. 
 ARTICLE II – EFFECTIVE DATE 
 Section 2.1 Effective Date. This Agreement shall automatically become effective as of the Execution Date (the “Effective
Date”), subject to termination and becoming null and void as of the Execution Date pursuant to the provisions of the Settlement Agreement. 
 ARTICLE III - PAYMENTS 
 Section 3.1 Net Sales Split Payments. 
 (a) In consideration of the supply of GSK Supplied Product by GSK (and its Affiliates) to PAR (and its Affiliates) under the terms and conditions of this
Agreement during the Term, in addition to the Supply Price, PAR shall make a Net Sales Split payment to GSK (or its Affiliate) with respect to the Generic Injection Product and the Generic [* * *] Product (the “Generic Injection
Net Sales Split”) that is equal to [* * *] percent ([* * *]%) of Net Sales of GSK Supplied Product in the Territory. 
 (b) In the event that it is determined, as evidenced by reasonable proof, that PAR (or an Affiliate) has knowingly sold, directly or indirectly to its wholesalers or distributors or other customers, any GSK Supplied Product outside of the
Territory, PAR shall, in lieu of the foregoing Net Sales Split, pay GSK (or its Affiliate) a Net Sales Split of [* * *] percent ([* * *]%) of the Net Sales (the “Diverted Product Net Sales Split”) of such
diverted GSK Supplied Product; provided, however, that the 

  

 8 

 Pursuant to 17 CFR 240.24b-2, confidential information has been omitted in places marked “[*
* *]” and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application filed with the Commission. 
  

 
calculation of such payment shall exclude any Net Sales on such diverted GSK Supplied Product that PAR successfully recalls and recovers within the thirty
(30) day period set forth in Section 4.3(b) (with such recalled GSK Supplied Product instead being subject to the Net Sales Split as set forth in Section 3.1(a) above when and if resold by PAR), and further provided that PAR shall
provide GSK with written evidence that is reasonably satisfactory to GSK as to such successful recall and recovery. Nothing in this paragraph shall in any way limit GSK’s remedies that may be available to it pursuant to this Agreement, and
shall in no way be deemed as permission for PAR to promote or sell, directly or indirectly, GSK Supplied Product outside the Territory. 
 Section 3.2. Net Sales Split Obligation Effective and Termination Dates. 
 (a) PAR’s Net Sales Split obligation to
GSK (or its Affiliate) for the Product shall automatically become effective in the Territory as of the Launch Date and shall automatically terminate as of the Supply Termination Date (except as otherwise set forth in Section 3.2(b) with respect
to post- Supply Term sales). 
 (b) Ten (10) days prior to the end of the Supply Term, PAR shall notify GSK of the amount of the GSK
Supplied Product PAR or its Affiliates then has on hand, the sale of which would, but for the termination of the Supply Term, be subject to the Net Sales Split, and PAR and its Affiliates shall thereupon be permitted to sell that amount of GSK
Supplied Product in accordance with the provisions of this Agreement in the Territory, for as long as it reasonably takes PAR to deplete the amount of the GSK Supplied Product PAR or its Affiliates then has on hand, provided that PAR shall pay to
GSK the Net Sales Split that would have accrued but for the termination of the Supply Term. 
 Section 3.3 Net Sales Reporting and
Payment. 
 (a) Within [* * *] ([* * *]) days after the end of each Calendar Quarter in which a sale of GSK Supplied
Product has been made by PAR (or its Affiliates) in the Territory, PAR shall submit to GSK and Spectrum a written report (the “Net Sales Split Report”) containing the following information regarding such preceding Calendar Quarter:
an itemized accounting and calculation of the total Net Sales of GSK Supplied Product sold by PAR (or its Affiliates) during such preceding Calendar Quarter in the Territory and the amount of any Net Sales Split due GSK on such Net Sales, and such
report shall include information in sufficient detail reasonably necessary for GSK to confirm the accuracy of the amount of the Net Sales Split due GSK, if any, during such preceding Calendar Quarter. Concurrent with the submission of a Net Sales
Split Report to GSK, PAR shall also remit payment to GSK of any and all Net Sales Split due GSK (or its Affiliate) for such preceding Calendar Quarter in the Territory. Upon request by GSK [***], PAR shall provide GSK with a non-binding estimate of
the gross number of units of GSK Supplied Product sold [***], to the extent such information has not been already provided to GSK in a Net Sales Split Report, and for the avoidance of doubt such estimate shall not in any way bind or commit PAR. All
Net Sales Split Reports shall be considered Confidential Information of both Parties. 
 (b) Prior to January 1, 2007, the Parties shall
in good faith develop procedures for the ongoing and timely exchange of the information necessary for the Parties to comply with the reporting obligations promulgated under the U.S. Deficit Reduction Act of 2005, including, but not limited to, the
“best price” and “AMP” calculations. In the event that any governmental agency (including, without limitation, the Center for Medicare and Medicaid Services or the Department of Health and Human Services Office of Inspector
General) subsequently promulgates regulations or otherwise provides 

  

 9 

 Pursuant to 17 CFR 240.24b-2, confidential information has been omitted in places marked “[*
* *]” and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application filed with the Commission. 
  

 
guidance which clarifies the Parties’ obligations under the U.S. Deficit Reduction Act of 2005, which may be applicable to this Agreement, then the
Parties shall meet to consider whether modifications to this Agreement or the procedures are appropriate. 
 (c) PAR agrees, represents and
covenants it (and its Affiliates) shall transport, store distribute, sell and promote GSK Supplied Product in the Territory in compliance with all Applicable Laws regarding the promotion and marketing of GSK Supplied Product, including, but not
limited to, with respect to the U.S. Federal Food, Drug and Cosmetics Act of 1938, as amended, and the Prescription Drug Marketing Act of 1987. PAR further agrees, represents and covenants that, as applicable, any calculated prices or other data or
information that are provided to GSK by PAR and/or its Affiliates for use by GSK for reporting purposes pursuant to the Deficit Reduction Act of 2005 (DRA), Pub. L. No.109-171, § 6001(c)(3) (2006), the 340B Drug Pricing Program and the
requirements of the Veterans Health Care Act of 1992(Public Law No. 102-585) Section 602, and Section 1927 of the Social Security Act, and any other similar federal or state government programs, shall to its knowledge be current,
accurate and complete and shall comply with applicable laws and regulations. 
 Section 3.4 Supply Price. 
 (a) The per unit supply price for the GSK Supplied Product purchased by PAR and its Affiliates from GSK pursuant to the terms of this Agreement is set
forth on Schedule 3.4(a) (the “Supply Price”). The Supply Price for GSK Supplied Product during any subsequent extension of the Supply Term pursuant to Section 4.1(b) shall be on such terms and conditions as negotiated
by the Parties in good faith at such time as the Supply Term is renewed, provided such Supply Price shall be no greater than as set forth on Schedule 3.4(a). 
 (b) PAR shall remit to GSK (or its Affiliate) payment of the applicable Supply Price (i.e., the Supply Price x units) for the GSK Supplied Product within [* * *] ([* * *]) days after the date of
GSK’s (or its Affiliate’s) invoice for each shipment of GSK Supplied Product to PAR and its Affiliates. With respect to the Supply Price relating to the Initial Quantity, PAR shall remit to GSK (or its Affiliate) payment of the applicable
Supply Price (i.e., the Supply Price x units) for the GSK Supplied Product within [***] after the Launch Date. 
 (c) Within thirty
(30) days prior to delivery of the Initial Quantity for GSK Supplied Product to PAR (or any of its Affiliates) pursuant to Section 4.2(d), PAR (or its applicable Affiliate) and GSK’s Affiliate “GlaxoSmithKline Trading Services
Limited” shall enter into an agreement in the form set forth in Schedule 3.4(c) (the “Trading Services Agreement”). For the avoidance of doubt, in the event of any inconsistency or conflict between the terms of the
Trading Services Agreement and this Agreement, the terms of this Agreement shall govern. 
 Section 3.5 Late Payments. Any
payment due GSK (or its Affiliate) from PAR (or its Affiliate) that is past due under this Agreement shall bear interest at a rate equal to the lesser of (i) Prime Rate plus [* * *] percent ([* * *]%) per year, or
(ii) the maximum rate permitted by Applicable Law, calculated based on the number of days that the payment is delinquent. 
 Section 3.6 Method of Payment. PAR shall make all payments to GSK (or its Affiliate) in lawful money of the United States by electronic transfer to an account designated by GSK (or its Affiliate) as designated in the Trading
Services Agreement, or by such other means as may be agreed in advance by both Parties. 
  

 10 

 Pursuant to 17 CFR 240.24b-2, confidential information has been omitted in places marked “[*
* *]” and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application filed with the Commission. 
  

 Section 3.7 Taxes. 
 (a) GSK shall be responsible for and shall pay all taxes payable on any income or any payments by PAR to GSK. PAR and GSK shall bear sole responsibility
for payment of compensation to their respective personnel, employees or subcontractors and for all employment taxes and withholding with respect to such compensation pursuant to Applicable Law. 
 (b) PAR shall have the right to withhold taxes in the event that the revenue authorities in any country require the withholding of taxes on amounts paid
hereunder to GSK (or its Affiliate). Any tax, duty or other levy paid or required to be withheld by PAR on account of Net Sales Splits, Supply Price or other payments payable to GSK under this Agreement shall be deducted from the amount of Net Sales
Splits, Supply Price or other payments due GSK. PAR shall secure and promptly send to GSK proof of such taxes, duties or other levies withheld and paid by PAR or its Affiliates for the benefit of GSK. Each Party agrees to cooperate with the other
Party in claiming exemptions from such deductions or withholdings under any agreement or treaty from time to time in effect. 
 Section 3.8 Records. PAR shall keep and require its Affiliates to keep complete and accurate records of all purchases and sales of GSK Supplied Product under the terms and conditions of this Agreement, pursuant to
Section 5.6. 
 Section 3.9 Net Sales Split Audit. Upon the written request of GSK (but not more frequently than [***]), GSK
shall have the right, within sixty (60) days after receipt of written confirmation that the Auditor is reasonably satisfactory to PAR (as set forth below), starting as of the Launch Date and during the Term of this Agreement [***], to have an
independent certified public accountant, satisfactory to PAR in PAR’s reasonable discretion (the “Auditor”) inspect PAR’s records with respect to the transactions contemplated by this Agreement for the preceding [***]
during the Term (but not more than one time for any period) for the sole purpose of determining the accuracy of PAR’s Net Sales Split Reports and the associated Net Sales Split payments made to GSK under this Agreement. PAR shall permit the
Auditor to have reasonable confidential access, during normal business hours and upon having given reasonable prior notice, to such records of PAR as may be necessary to verify PAR’s compliance with the Net Sales Split payments due hereunder
for the [***]. The Auditor shall reach its conclusion as quickly as possible but in no event more than a period of thirty (30) days, and notify the Parties and Spectrum of its conclusion in writing. Under no circumstances shall the Auditor
report to GSK or Spectrum the wholesale prices at which PAR sold the GSK Supplied Product. In the event the Auditor concludes that there was an underpayment of the Net Sales Split to GSK, the underpayment shall be paid by PAR within thirty
(30) days after the date PAR receives such Auditor’s written report. In the event the Auditor concludes that there was an overpayment of the Net Sales Split to GSK, the overpayment shall be credited toward future Net Sales Split payments
to be paid by PAR to GSK under this Agreement; provided, however, that in the event no further Net Sales Split payments shall become due under this Agreement, said overpayment shall be paid by GSK to PAR within thirty (30) days after the date
GSK receives such Auditor’s written report. If the underpayment of the Net Sales Split is greater than [* * *] percent ([* * *]%) of the Net Sales Split determined by the Auditor to be payable to GSK, the reasonable fees and
expenses charged by the Auditor shall be paid by PAR, otherwise GSK shall pay the reasonable fees and expenses charged by such Auditor. The Auditor shall report to GSK only its conclusions as to whether PAR is in compliance with the Net Sales Split
obligations and the amount of any underpayment or overpayment. The Auditor inspecting records of PAR shall sign a written confidentiality agreement reasonably satisfactory to PAR and GSK. 
  

 11 

 Pursuant to 17 CFR 240.24b-2, confidential information has been omitted in places marked “[*
* *]” and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application filed with the Commission. 
  

 ARTICLE IV – SUPPLY 
 Section 4.1 Supply Term. 
 (a)
GSK (or its Affiliate) shall use its Commercially Reasonable Efforts to supply PAR and its Affiliates with their entire commercial requirements of GSK Supplied Product for sale to PAR’s (and its Affiliates’) distributors and other
customers solely in the Territory pursuant to the provisions of this Agreement, including those provisions regarding the timing of such supply. GSK’s (or its Affiliate’s) supply obligation for GSK Supplied Product shall be for the duration
of the Supply Term subject to Section 4.1(b). 
 (b) The Supply Term for the Product may be extended for additional one (1) year
periods beyond its then-applicable expiry date. In the event either Party wishes to extend the Supply Term for an additional one (1) year period beyond its applicable expiry date, such Party shall submit such request in writing to the other
Party at least nine (9) months before the Supply Term’s then applicable expiry date. Within thirty (30) days after the receipt of such request, the recipient Party shall respond to the extension-requesting Party in writing as to
whether or not the recipient Party accepts such request for a one (1) year extension of the Supply Term; provided, neither Party shall be bound to such extension until a Supply Price has been agreed-upon pursuant to Section 3.4(a). For the
avoidance of doubt, GSK shall not be obligated to extend the Supply Term if, in GSK’s reasonable discretion, the Supply Price for the extension period should exceed the prices set forth in Schedule 3.4(a). Notwithstanding anything to the
contrary, the Supply Term shall automatically terminate as of the earlier of the date upon which this Agreement terminates or expires for any reason. 
 (c) In the event the Launch Date occurs [***], PAR (and its Affiliates) hereby acknowledge and agree that [***]. In the event [***] pursuant to the provisions of this Agreement. [***] 
 (d) [* * *], such product shall [***] 

  

 12 

 Pursuant to 17 CFR 240.24b-2, confidential information has been omitted in places marked “[*
* *]” and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application filed with the Commission. 
  

 
shall be deemed to [* * *] provided, if [***]. For the avoidance of doubt, [* * *]. 
 Section 4.2 Supply Provisions. 
 (a) Exclusive Supply. 
 (i) PAR hereby agrees and acknowledges that, subject to the terms and conditions of this Agreement,
PAR and its Affiliates shall receive one hundred percent (100%) of its (and its Affiliates’) requirements of Generic Injection Product and Generic [* * *] Product in the Territory from GSK (or GSK’s Affiliates) during the
Supply Term. PAR hereby agrees and acknowledges that, during the Supply Term, PAR (and its Affiliates) shall not, directly or indirectly, purchase, receive, make, have made, use, sell, offer for sale or import any Product, as applicable, in the
Territory with the sole exception of its rights to market and sell GSK Supplied Product in the Territory as explicitly set forth in this Agreement and as permitted in the Settlement Agreement. 
 (ii) GSK agrees and acknowledges that from the Execution Date until the Supply Termination Date
(subject to Section 4.1(d), if applicable) GSK (and its Affiliates) shall not, directly or indirectly, through a Third Party sell or supply for import/export any Generic Injection Product or any Generic [* * *] Product
([* * *]). Notwithstanding the foregoing, PAR agrees and acknowledges that nothing in this Agreement shall prohibit GSK and its Affiliates from making, having made, using, selling to any Person, having sold to any Person, and importing
Products approved by the FDA as of the Execution Date or other components of Generic Injection Products or the Generic [* * *] Products (including the Product) in the Territory in each case under an applicable GSK brand name, label or
trademark (including the Imitrex® trademark) with the exception of a Generic Equivalent of
the Imitrex® [* * *]. Subject to the first sentence of this Section 4.2(a)(ii), nothing in this Agreement shall prohibit GSK and its Affiliates from making,
or having made, or using, or selling or having sold or importing (individually, or as a blend), the components of the Generic Injection Product or the Generic [* * *] Product for sale (individually, or as a blend) by GSK or its Affiliates
or any Third Party in the Territory during and after the Supply Term. GSK hereby represents [* * *]. 
 (iii)
Failure to Supply. In the event of [* * *] prior to the [***] (for any reason except as set forth below [***] with at least [* * *] that are consistent with the [* * *]. Further provided in no event shall 

  

 13 

 Pursuant to 17 CFR 240.24b-2, confidential information has been omitted in places marked “[*
* *]” and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application filed with the Commission. 
  

 
[* * *] shall be as determined on a [***] shall use [***] in the event of such a [***]. 
 (b) Specifications and Supply. GSK hereby represents, warrants and covenants that all GSK Supplied Product shall, with the exception of
information provided to GSK by PAR: (i) not be misbranded or adulterated under Applicable Law, (ii) be in fully finished form, labeled and packaged for supply to the ultimate consumer in accordance with Applicable Law, (iii) meet the
applicable specifications and requirements set forth in Schedule 4.2(b)(iii), (iv) be manufactured, labeled, packaged and stored in accordance with specifications in the applicable NDA, cGMP, and Applicable Law and (v) be capable of
maintaining conformity to said specifications and requirements when handled and stored in accordance with the Labeling until the applicable expiry date of such GSK Supplied Product. GSK (or its Affiliate) may have manufactured, and supplied to PAR,
GSK Supplied Product from any of GSK’s (or its Affiliates or its or their supplier’s or subcontractor’s) FDA approved and registered manufacturing facilities. All GSK Supplied Product shall be supplied to PAR and its Affiliates in
compliance with Applicable Law, including cGMP and the Quality Agreement (“Quality Agreement”), which shall be entered into by the Parties within thirty (30) days after the Execution Date (but in any event prior to the release
of the Initial Quantity to PAR) and shall be substantially in the form set forth in Schedule 4.2(b). GSK shall use commercially reasonable efforts to promptly respond to any reasonable inquiries from PAR regarding the supply of GSK Supplied
Product. 
 (c) Ordering/Forecasting. 
 (i) Except as is set forth below with regard to the Initial Quantity during the Supply Term, at least [* * *] ([* * *]) days prior to the start of each calendar month, PAR shall provide GSK (or its
Affiliate) with a written firm order for such upcoming calendar month. By the first of each calendar month, PAR shall also provide GSK (or its Affiliate) with a written estimate of the quantities of GSK Supplied Product in the Territory PAR and its
Affiliates require for the next succeeding [* * *] ([* * *]) months on a monthly basis (in the forecast format set forth on Schedule 4.2(c)) (the “Forecast”). Each of such Forecast shall contain the
applicable [* * *] ([* * *]) calendar months firm orders and the remaining [* * *] ([* * *]) non-binding monthly estimates for that applicable period. When PAR shall place a firm order with GSK (or its
Affiliate) for its GSK Supplied Product requirements at least [* * *] ([* * *]) days in advance of the start of each calendar month, GSK (or its Affiliate) shall respond to PAR within [* * *] ([* * *])
Business Days after receipt of such firm order, and in the event GSK (or its Affiliate) responds other than by accepting the firm order, the Parties shall cooperate and use good faith efforts to meet as closely as reasonably possible the Reasonable
Quantity Requirements and schedule for delivery specified in the firm order, subject to the provisions of subsections (ii) below. Once a firm order is agreed upon by the Parties, PAR shall amend the firm order to reflect the quantity and
delivery schedule agreed by the Parties and send to GSK (or its Affiliates) such revised firm order and a purchase order covering such quantities and delivery date, and GSK (or its Affiliate) shall have the obligation to supply such quantity to PAR
pursuant to the terms hereof. PAR shall promptly reimburse GSK for any 

  

 14 

 Pursuant to 17 CFR 240.24b-2, confidential information has been omitted in places marked “[*
* *]” and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application filed with the Commission. 
  

 
and all documented, reasonable costs and expenses incurred by GSK (or its Affiliate) that arise from any canceled or materially modified firm order (without
GSK’s prior written consent) after acceptance thereof by GSK (or its Affiliate), including all obsolete material that can not be reasonably utilized by GSK or its Affiliate. The previous sentence shall not limit GSK’s remedies or damages
in the event PAR cancels or materially modifies any firm order, and PAR shall not modify or cancel the last firm order in the Supply Term. In the event the Parties reasonably agree that a Third Party Generic Sumatriptan Product is likely to in the
immediate future, or has, become available for commercial sale in the Territory, the Parties shall in good faith review and adjust the then-existing Forecast in light of the presence of such Third Party Generic Sumatriptan Product in the Territory,
provided the Parties shall use their commercially reasonable efforts to mitigate all losses and expenses related to such revisions to the Forecast. 
 The last firm order and Forecast shall be received and agreed by GSK not less than [* * *] ([* * *]) days prior to the Supply Termination Date. The firm orders for the last [* * *]
([* * *]) months of the Supply Term shall each not exceed [* * *] percent ([* * *]%) of the average monthly demand for GSK Supplied Product over the prior twelve (12) month period (determined on a sku-by-sku
basis), unless PAR can provide reasonable evidence to GSK that there is adequate demand over the remainder of the Supply Term for GSK Supplied Product in excess of such limits. Upon termination or expiration of this Agreement, all firm orders and
Forecasts are to be automatically terminated, except to the extent that backordered firm orders remain unfilled. PAR acknowledges and agrees that GSK relies on the [* * *] ([* * *]) month firm zone orders provided by PAR for the purpose of
manufacturing planning and ordering necessary materials and components for the production of GSK Supplied Product. In the event PAR does not issue purchase orders in a timely manner (as described in this Section 4.2(c)) covering any [* * *] ([*
* *]) month firm zone, PAR agrees that in the event GSK decides in its sole discretion to waive the firm zone requirements set forth herein: (A) GSK is entitled to reasonably rely upon the applicable [* * *] month firm zone last provided by PAR
in the Forecast for the purpose of manufacturing planning and ordering necessary materials and components for the production of GSK Supplied Product and (B) in the event GSK is unable to reasonably utilize any such materials and components in
the event PAR’s purchase orders are less than as set forth in the firm orders for such [* * *] ([* * *]) month firm zone, PAR shall reimburse GSK for all reasonable out-of-pocket costs incurred by GSK for any such obsolete materials and
components, provided GSK uses its reasonable efforts to mitigate the costs associated with such obsolete materials and components. For the avoidance of doubt, GSK shall, in its sole discretion, decide whether or not it (or its Affiliates) will
supply PAR with GSK Supplied Product absent purchase orders issued in a timely manner (as described in this Section 4.2(c)) for any [* * *] ([* * *]) month firm zone, however GSK shall reasonably consider supplying PAR in such instance,
consistent with GSK’s reasonable ability to do so. 
 (ii) Each purchase order shall specify a delivery date which shall be at least [*
* *] ([* * *]) days after the date of the purchase order. Should a purchase order call for shipment of quantities of GSK Supplied Product in excess of [* * *] percent ([* * *]%) of the immediately preceding estimated requirements previously provided
to GSK (or its Affiliate) in the Forecast, GSK (or its Affiliate) will use its Commercially Reasonable Efforts, but shall not be obligated, to supply that portion of excess by the dates instructed by PAR; provided, however, in no event shall GSK (or
its Affiliates) have any obligation to forego manufacture of any GSK (or its Affiliates’) products on common equipment that would have a material adverse consequence to GSK business in order to deliver GSK Supplied Product to PAR or its
Affiliates in excess of the preceding Forecast. Notwithstanding anything to the contrary, PAR’s first firm orders for the [* * *] ([* * *]) month firm zone for GSK Supplied Product from GSK shall be in the quantities specified in
Schedule 4.2(d). GSK (and its Affiliates) shall not be obligated to supply to PAR (or its Affiliates) quantities of GSK Supplied Product in excess of GSK’s (or 

  

 15 

 Pursuant to 17 CFR 240.24b-2, confidential information has been omitted in places marked “[*
* *]” and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application filed with the Commission. 
  

 
its Affiliate’s) branded Imitrex® [* * *] product ([* * *]presentations) manufacturing capacity (with such capacity being defined herein as GSK’s [* * *] product ([* * *]
presentations) capacity without regard to individual presentation capacity – all subject to PAR’s compliance with the forecasting and firm order requirements in this Agreement). In no event shall such capacity be less than such capacity
existing as of the Execution Date. 
 (iii) Delivery of GSK Supplied Product ordered hereunder from GSK (or its Affiliate) to PAR and its
Affiliates shall be [***] (Incoterms 2000), whereby [***] and [***] shall bear all risk of loss or damage, and costs of insurance and shipping associated with the GSK Supplied Product [***]. 
 (iv) Attached hereto as Schedule 4.2(d), is PAR’s current good faith non-binding estimate of its (and its Affiliates’) requirements of
GSK Supplied Product for the Territory for the [* * *] ([* * *]) months (including the Initial Quantity) following the Launch Date and the remainder of the Forecast. Following the Execution Date, PAR shall provide GSK an updated version of
the Forecast on a [* * *] basis. [* * *] ([* * *]) days after the later of (A) [***] and (B) the date GSK notifies PAR of its ability (or inability) to supply PAR with the Generic [* * *] Product in the
[* * *], PAR shall provide GSK with a definitive Forecast (in the form applicable to such Launch Date) and binding purchase orders for the [* * *] ([* * *]) months following the Launch Date (such total to include the Initial
Quantity) and such Forecast and binding purchase orders shall not vary by more than [* * *] percent ([* * *]%) from the last non-binding Forecast provided to GSK (as determined on a monthly basis) subject to the last sentence of the first paragraph
of Section 4.2(c)(i). 
 (v) In ordering and delivering GSK Supplied Product, as the case may be, GSK (or its Affiliates) and PAR may
use their respective standard forms and documents in ordering and delivering the GSK Supplied Product, provided that nothing in those forms or documents shall be construed to modify or amend the terms and conditions of this Agreement, and, in the
case of any conflict herewith, the terms and conditions of this Agreement shall control. 
 (d) Initial Quantity. 
 (i) PAR’s good faith estimate of the initial quantity of GSK Supplied Product that GSK (or its Affiliate) shall supply PAR and its Affiliates is
set forth on Schedule 4.2(d) hereto (the “Initial Quantity”). So as to allow GSK an appropriate opportunity to manufacture such Initial Quantity, the Initial Quantity [* * *]. GSK (or its Affiliate) shall deliver the Initial
Quantity to PAR (pursuant to Section 4.2(c)(iv)) at least [* * *] days prior to the anticipated Launch Date. 
 (ii) Title to the
Initial Quantity will remain with GSK until the Launch Date, and upon the Launch Date title to the Initial Quantity shall automatically transfer to PAR; [***]. [***] will store the Initial Quantity in one of its facilities until the Launch Date and
shall not, directly or indirectly, make available, consign, transfer, sell or make available for sale (or any other conveyance whatsoever) the Initial Quantity until the Launch Date occurs. On the Launch Date, [***]. 

  

 16 

 Pursuant to 17 CFR 240.24b-2, confidential information has been omitted in places marked “[*
* *]” and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application filed with the Commission. 
  

 (iii) The Parties shall use their Commercially Reasonable Efforts to make all reasonable
manufacturing preparations to enable GSK to be able to meet the obligations set forth in Section 4.2(d)(i) above, and as of the Execution Date, the Parties shall exercise their reasonable efforts, and shall co-operate with each other, to obtain
all necessary certifications, permits and other registrations required pursuant to Applicable Law to enable GSK (or its Affiliate) to manufacture and supply, and PAR and its Affiliates to import/export, sell and distribute, the GSK Supplied Product
pursuant to the provisions of this Agreement. 
 (e) Labeling. All GSK Supplied Products shall bear a generic label specifying PAR as
the distributor and displaying the logo PAR artwork supplied by PAR to GSK, and as agreed by GSK pursuant to the remainder of this Section 4.2(e). The label shall also include any references to Spectrum as conveyed by PAR and Spectrum to GSK in
accordance with the Applicable Law, [***]. All GSK Supplied Product Labels, packaging or trade dress [***] shall comply with Applicable Law (including the terms of the applicable NDA), and, subject to the first sentence of this Section 4.2(f),
[***]. Should PAR or GSK desire or be required pursuant to Applicable Law to make any change in any such Labels or Labeling, GSK shall be responsible for procuring the updating of all artwork and text associated with such change and providing such
changes to PAR. Upon approval by GSK, GSK shall make all necessary arrangements for such changed Labels or Labeling to be printed and shall provide to PAR agreed artwork documents for PAR’s review. PAR shall, within one (1) week of receipt
of agreed artwork documents, either provide GSK any necessary corrections thereto or notify GSK of its approval of such agreed artwork documents. [***] If a change of Labels or Labeling that was requested by PAR, required pursuant to Applicable Law,
or due to an assignment of this Agreement by Spectrum pursuant to Section 9.1 results in obsolete inventory of former Labels or Labeling that GSK cannot otherwise use, [***]. PAR shall supply GSK with all of PAR’s necessary artwork, text,
SKU numbers and other necessary items by the dates reasonably requested by GSK, so that GSK can prepare the Labels and packaging for the Initial Quantity. GSK’s obligations to supply PAR and its Affiliates with GSK Supplied Product, including
the Initial Quantity by the specified delivery date, shall be contingent upon GSK’s timely receipt of the foregoing artwork, text, SKU and NDC numbers and other necessary items from PAR. 
  

 17 

 Pursuant to 17 CFR 240.24b-2, confidential information has been omitted in places marked “[*
* *]” and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application filed with the Commission. 
  

 (f) Manufacturing. PAR and GSK hereby agree to follow and conduct their respective activities
in accordance with the terms of Applicable Law, the Quality Agreement and this Agreement. GSK (or its Affiliate) expressly reserves the right to select, and subsequently change, the manufacturing sites for the GSK Supplied Product at its sole
discretion, and will provide not less than one hundred eighty (180) days prior notice to PAR if the manufacturing of the GSK Supplied Product is to be moved to a site other than those identified in the applicable NDA provided, however, that GSK
shall only use manufacturing sites registered with FDA and in compliance with Applicable Law, and shall ensure that its selection or change of manufacturing sites will not: (i) adversely affect its ability to fulfill its then current supply
obligations to PAR and its Affiliates pursuant to this Agreement; or (ii) cause PAR or its Affiliates to incur additional material expenses or costs. In the event that GSK (or its Affiliate) desires to make a change of manufacturing sites that
will adversely affect the supply obligations described in the immediately preceding sentence, then GSK shall at its own risk of loss, use its Commercially Reasonable Efforts to stockpile such quantities of GSK Supplied Product as may be required to
deliver up to the volume of GSK Supplied Product ordered by PAR and its Affiliates pursuant to this Agreement. Subject to this Section 4.2(f), GSK (or its Affiliate) may dual-source the GSK Supplied Product from any FDA-registered facilities
without prior notice to PAR; provided GSK provides PAR with the ability to identify the manufacturing facility for each lot. 
 (g)
Delivery. GSK (or its Affiliate) shall use its Commercially Reasonable Efforts to deliver, pursuant to Section 4.2(c)(iii), to PAR and its Affiliates all such GSK Supplied Product as may be ordered by PAR and its Affiliates under a
purchase order issued to GSK (or its Affiliate) pursuant to this Agreement no earlier than [* * *] ([* * *]) days prior to the delivery date specified in PAR’s purchase order, and shall deliver such GSK Supplied Product no later than [* * *]
([* * *]) days after the date specified in PAR’s purchase order unless otherwise agreed. PAR shall pick-up the GSK Supplied Product on the applicable delivery date and pursuant to Section 4.2(c)(iii) and Section 4.2(d)(i) as
applicable. Nothing herein shall be construed as limiting the Parties’ ability to mutually agree in writing to any adjustment to a delivery date without any modification to a then outstanding purchase order or Forecast. GSK (or its Affiliate)
shall provide an invoice and a certificate of conformance (except that with respect to the Initial Quantity such certificate shall be supplied as set forth in Section 4.2(d)(i)) to PAR for each lot of GSK Supplied Product shipped to PAR and its
Affiliates which certifies that such GSK Supplied Product meets cGMP and meets the applicable specifications set forth in Schedule 4.2(b)(iii). 
 (h) Rejection and No Returns to GSK. Within [* * *] ([* * *]) days of receipt of any GSK Supplied Product, PAR and its Affiliates may perform appropriate inspections to determine whether the GSK Supplied
Product meets the applicable specifications set forth in Schedule 4.2(b)(iii) and in accordance with the Quality Agreement and the requirements of this Agreement. Any GSK Supplied Product not refused by PAR within [* * *] ([* * *]) days of
receipt of shipment shall be deemed accepted by PAR. If PAR wishes to refuse acceptance, PAR shall within such [* * *] ([* * *]) days time, inform GSK in writing of its refusal to accept the batch(s), and the reasons therefor. If the Parties do not
agree on the refusal or rejection of GSK Supplied Product, then either Party may refer the matter for final review to an independent Third Party of national reputation reasonably acceptable to both Parties for the purpose of determining the results.
Any determination by such Third Party shall be binding upon both Parties. The cost of any such review and evaluation by an independent Third Party shall be borne by PAR if it is determined that the GSK Supplied Product conforms to the requirements
of this Agreement, and by GSK if determined that it does not. GSK shall, as promptly as is reasonably possible, either (i) make replacement delivery of conforming GSK Supplied Product, with GSK bearing the reasonable expenses associated
therewith, or (ii) issue the appropriate credits to PAR, as requested by PAR. PAR shall, in 

  

 18 

 Pursuant to 17 CFR 240.24b-2, confidential information has been omitted in places marked “[*
* *]” and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application filed with the Commission. 
  

 
GSK’s reasonable discretion, either return to GSK or destroy any non-conforming GSK Supplied Product and provide to GSK written certification of
destruction, with GSK bearing the reasonable expenses associated therewith, including reasonable destruction, transportation and reasonable handling costs, as applicable. Except as set forth in this Section 4.2(h) with respect to initial
inspection of GSK Supplied Product, all sales of product from GSK to PAR shall be deemed final and non-returnable to GSK (except as provided for in Section 5.8(b)), and PAR shall be responsible for and shall process any and all aspects of its
customer returns of GSK Supplied Product to PAR (except as provided for in Section 5.8(b). 
 (i) PAR shall have the right, not more
than once annually and upon providing GSK with thirty (30) Business Days advance written notice, to inspect GSK’s factory (or factories, as applicable) that produce GSK Supplied Product for PAR, on a confidential basis and during normal
business hours, for the sole purposes of ensuring such factory(ies) compliance with applicable cGMP and Applicable Law solely related to the manufacturing and storage of GSK Supplied Product. PAR’s inspection rights under this Section shall be
limited to two (2) people for three (3) days, and shall not extend to any portions of such factory(ies), documents, records or other information which do not directly relate to the GSK Supplied Product. Inspection by PAR or documentation
provided to PAR related to any of GSK’s suppliers or subcontractors related to the manufacturing and storage of GSK Supplied Product is subject to consent of such GSK supplier or subcontractor. 
 Section 4.3 Marketing and Sale of GSK Supplied Product. 
 (a) PAR hereby agrees, represents and covenants that it shall, and it shall ensure that its Affiliates likewise agree, represent and covenant, for the Supply Term: 
 (i) not seek or accommodate customers, or establish any branch or maintain any distribution depot, for GSK Supplied Product outside the Territory;

 (ii) restrict its marketing, promotion, advertisement, sale and distribution of the GSK Supplied Product solely within the Territory, in
accordance with the Applicable Laws; 
 (iii) not sell, market, promote, advertise, or distribute the GSK Supplied Product outside the
Territory; 
 (iv) not sell GSK Supplied Product to any Third Party in the Territory for resale outside the Territory; and 
 (v) not knowingly, directly or indirectly, sell GSK Supplied Product outside the Territory via the Internet or mail order. 
 (b) In the event, as evidenced by reasonable written proof, PAR has breached any of the provisions of subsection (a) above, GSK shall provide
written notice to PAR briefly summarizing its evidence of such breach. PAR shall immediately take appropriate actions to remedy such breach, including halting such sales, implementing procedures to ensure such breach does not re-occur, and recalling
all such exported GSK Supplied Product, within thirty (30) days after receipt of notice thereof by GSK. Nothing in this paragraph shall in any way limit GSK’s remedies that may be available to it pursuant to this Agreement, including the
right to terminate this Agreement for such breach pursuant to Section 7.2(a). 
  

 19 

 Pursuant to 17 CFR 240.24b-2, confidential information has been omitted in places marked “[*
* *]” and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application filed with the Commission. 
  

 (c) PAR shall use its Commercially Reasonable Efforts to market and sell GSK Supplied Product to its
distributors and other customers in the Territory, pursuant to the terms of this Agreement, for the duration of the Supply Term. PAR shall be solely responsible, at its expense, for all activities related to the sale, marketing, warehousing,
shipping and distribution of the GSK Supplied Products in the Territory, including but not limited to advertising, pricing, customer contracting, maintenance of toll-free consumer telephone lines, processing of consumer mailers, maintenance of
required websites and databases. [***] 
 (d) [***] 
 Section 4.4 Pharmacovigilance. 
 The Parties shall within thirty (30) days prior to the
delivery of the applicable Initial Quantity of GSK Supplied Product, enter into a Pharmacovigilance Agreement for the GSK Supplied Products substantially in the form attached hereto as Schedule 4.4 (the “Pharmacovigilance
Agreement”). 
 Section 4.5 Advertising, Marketing and Promotional Materials. PAR shall be solely responsible for
designing, preparing and distributing, at its sole expense and control, all advertising, marketing and promotional materials (including all written, printed, electronic, audio or video matter) used in its (or PAR’s Affiliates’) promotion,
detailing, advertising and marketing of the GSK Supplied Product within the Territory (collectively “Promotional Materials”). For the avoidance of doubt, Promotional Materials shall not constitute Labels or Labeling hereunder. PAR will
ensure that all of its Promotional Materials comply with, and all of its other advertising, marketing and promotional activities comply with, and PAR will be solely responsible and liable for any failure of such materials and activities to comply
with, the applicable labeling and the applicable NDA and with Applicable Law, notwithstanding that such materials may have been previously reviewed or used by GSK (or its Affiliate). PAR shall be solely responsible for fulfilling regulatory
requirements pertaining to its promotional activities, including without limitation sole responsibility for submitting all Promotional Materials prepared by or for it to the FDA at the time of initial dissemination by way of a Form FDA-2253,
consistent with 21 CFR Section 314.81. To this effect, GSK will promptly place a letter on file with DDMAC with respect to the GSK Supplied Product, advising DDMAC that PAR (or its Affiliate) will be marketing and promoting the GSK Supplied
Product and filing with DDMAC Form FDA-2253 for all promotional labeling and materials. Each Party agrees promptly to provide the other Party with a copy of any correspondence from a government agency relating to the GSK Supplied Product, including
but not limited to the FDA, reflecting regulatory action being considered or taken by such government agency, 

  

 20 

 Pursuant to 17 CFR 240.24b-2, confidential information has been omitted in places marked “[*
* *]” and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application filed with the Commission. 
  

 
including without limitation copies of FDA Untitled Letters and Warning Letters. For avoidance of doubt, to the extent any of these correspondence or other
materials provided to the other Party contain pricing information, such materials shall be redacted prior to providing the other Party with a copy thereof. PAR will absorb and be solely responsible for any damages, losses, expenses and costs
incurred by PAR or GSK, its/their Affiliates, and its/their representatives and agents, arising from the failure of any Promotional Materials developed by PAR (or its Affiliate) and any promotional, advertising or marketing activities by PAR (or its
Affiliate) to comply with the applicable labeling, the applicable NDA and with Applicable Law. Notwithstanding the foregoing, GSK will absorb and be solely responsible for any damages, losses, expenses and costs incurred by PAR or GSK, its/their
Affiliates, and its/their representatives and agents, arising from the failure of any Labels or Labeling that were developed by GSK (or its Affiliate) for its branded Imitrex® product and used in GSK Supplied Product to comply with the applicable NDA and with Applicable Law. If PAR (or GSK)
receives an Untitled Letter or a Warning Letter on Promotional Materials relating to the Supplied Product: (i) PAR will fully cooperate with GSK, pursuant to Applicable Law, in responding to the FDA (or other applicable governmental agency),
and (ii) PAR shall immediately cease its use of such Promotional Material; and (iii) PAR shall, for a period of twelve (12) months thereafter, prior to the use or dissemination of any Promotional Materials submit such Promotional
Materials for prior review and approval by DDMAC and shall not use any such Promotional Materials until approved by DDMAC. For the avoidance of doubt, except for such responsibilities and liabilities attributable to GSK under Applicable Law, GSK
(and its Affiliates) shall have no responsibilities or liabilities whatsoever with respect to the Promotional Materials and promotional, advertising or marketing activities relating to PAR’s Generic Injection Product or Generic [* * *] Product.

 ARTICLE V - REPRESENTATIONS, WARRANTIES AND COVENANTS 
 Section 5.1 Mutual Representations and Warranties. Each of the Parties hereby represents, warrants and covenants to the other Party as of the Execution Date, as follows: 
 (a) It is an entity duly organized, validly existing and is in good standing under the laws of its jurisdictions of formation, and has all requisite power
and authority, corporate or otherwise, to execute, deliver and perform this Agreement. 
 (b) The execution, delivery and performance of this
Agreement have been duly authorized by all necessary corporate action and do not and will not (i) require any consent or approval of its stockholders, (ii) violate any provision of any Applicable Law or any provision of its certificate of
incorporation, by-laws or other founding document, or (iii) result in a breach of or constitute a default under any material agreement, mortgage, lease, license, permit or other instrument or obligation to which it is a party or by which it or
its properties may be bound or affected. 
 (c) It (and its Affiliates) are not currently debarred, suspended or otherwise excluded by any
government agency from receiving government contracts in the Territory, nor is it, or its Affiliates or any of its employees debarred under the applicable provisions of the Food, Drug, and Cosmetic Act. 
 (d) It is not under any obligation to any Third Party, or entity, contractual or otherwise, that is conflicting or inconsistent in any respect with the
terms of this Agreement or that would impede the diligent and complete fulfillment of its obligations hereunder. 
  

 21 

 Pursuant to 17 CFR 240.24b-2, confidential information has been omitted in places marked “[*
* *]” and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application filed with the Commission. 
  

 (e) This Agreement is a legal, valid and binding obligation enforceable against it in accordance with
its terms and conditions, except as such enforceability may be limited by applicable bankruptcy, insolvency, moratorium, reorganization or similar laws, from time to time in effect, affecting creditor’s rights generally. 
 Section 5.2 Survival of Representations, Warranties and Covenants. Except as set forth in Section 7.3(c), the representations,
warranties and covenants contained in this Article V shall survive the execution and delivery of this Agreement by the Parties and shall expire on the Supply Termination Date. 
 Section 5.3 Additional Representations/Covenants. Each Party hereby agrees, represents and covenants it shall perform all of its respective
obligations, responsibilities and duties under this Agreement in full compliance with all Applicable Law, and in no event shall either Party be required to conduct any activities or undertake any actions hereunder that are contrary to Applicable
Law. 
 Section 5.4 Notwithstanding anything in this Agreement to the contrary, the Parties acknowledge and agree that no rights are
conveyed to PAR under this Agreement with respect to distributing, marketing, selling or promoting Product as non-prescription drugs in the over-the-counter market, or in the animal health market, and PAR further acknowledges and agrees that neither
it nor any of its Affiliates shall engage in any marketing, promotion, advertisement, sale or distribution of Product as non-prescription drugs in the over-the-counter market, or in the animal health market. 
 Section 5.5 No Additional Rights. 
 (a) PAR hereby acknowledges and agrees that nothing in this Agreement shall grant to PAR (or its Affiliates) any rights to any new formulations, indications, dosages, forms of administration or other presentations of Product at any time
derived or developed by or on behalf of GSK (or its Affiliates), or any other product, compound or molecule owned or controlled by GSK (or its Affiliates). 
 (b) Except as provided herein, PAR hereby acknowledges and agrees that no rights to make or have made Generic Injection Product or Generic [* * *] Product in the Territory, and no rights to import, make, have made,
use, sell or offer for sale Generic Injection Product or Generic [* * *] Product in any other region of the world outside the Territory, are granted to PAR or its Affiliates in this Agreement. 
 (c) For the avoidance of doubt, the Parties agree that, subject to Section 4.2(a)(ii), GSK, and its Affiliates, retain and reserve all rights to
make, have made, use, sell, import Product or otherwise exploit on its own or with any Third Party any and all GSK or its Affiliate’s intellectual property (including patents, patent applications, know-how, trade secrets, copyrights, trade
dress, housemarks and trademarks) for any purpose or use in any region of the world, and PAR hereby agrees and acknowledges it has no rights, explicit or implicit, to use or otherwise exploit such GSK (and its Affiliates’) intellectual property
for any purpose, except as is explicitly set forth in this Agreement or the Settlement Agreement. 
 (d) Nothing in this Agreement shall be
deemed or implied to be, and the Parties disclaim all implied rights to, the grant by any of the Parties to the other Party of any right, title or interest in any product, intellectual property rights (including patents, patent applications,
know-how, trade secrets, copyrights, trade dress, housemarks and trademarks), any formulation technology or know-how, manufacturing technology or know-how, operating procedures, marketing materials or strategies, 

  

 22 

 Pursuant to 17 CFR 240.24b-2, confidential information has been omitted in places marked “[*
* *]” and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application filed with the Commission. 
  

 
intangibles, material or proprietary rights of the other except as are expressly set forth in this Agreement. For purposes of clarity, nothing in this
Paragraph shall curtail PAR’s right to promote, offer for sale, sell and distribute the GSK Supplied Product as otherwise permitted in this Agreement. 
 (e) For the avoidance of doubt, GSK shall have no responsibilities or obligations whatsoever with respect to any NDA or ANDA obtained or held by PAR or Spectrum (or any of their Affiliates) or any Third Party, or any
product manufactured, marketed or sold pursuant thereto except as provided in Paragraph 8 of the Settlement Agreement. For the avoidance of doubt, nothing in this Agreement shall be deemed in any way whatsoever to be an explicit or implied license
or other grant of rights to PAR (or its Affiliates) or any Third Party to use or exploit in any way whatsoever any of GSK’s (or its Affiliates’) owned or controlled intellectual property (including patents, patent applications, know-how,
trade secrets, copyrights, trade dress, housemarks and trademarks) with respect to any Product, directly or indirectly, imported, supplied, manufactured, or sold by or on behalf of PAR (or its Affiliates) or any Third Party that is not GSK Supplied
Product. 
 Section 5.6 Records. Each of the Parties (and their respective Affiliates) shall keep complete and accurate written
records of all of its activities associated with or regarding this Agreement to the extent commercially reasonably possible. All such applicable records shall be maintained by the Parties (or their respective Affiliates), as applicable, for the
period required by Applicable Law or a period of seven (7) years from the date of the record’s creation, whichever is longer. 
 Section 5.7 Regulatory Matters. 
 (a) GSK (or its Affiliate) shall obtain, maintain, or shall cause to be obtained or
maintained, all regulatory and governmental permits, licenses, registrations, certifications, authorizations and approvals for the GSK Supplied Product that are necessary for GSK (or its Affiliate) to manufacture, sell, process, distribute, package
and label the GSK Supplied Product to and for PAR and its Affiliates in accordance with the terms of this Agreement and Applicable Law. GSK warrants that it (or its Affiliate) has an FDA approved NDA(s) and Drug Master File(s) for the GSK Supplied
Product, and that it (or its Affiliate) has appropriate registrations, approvals, facilities and the ability to manufacture, package and label the GSK Supplied Product in accordance with cGMPs and Applicable Law. In addition to fulfilling other
regulatory requirements pursuant to Applicable Law, PAR shall obtain its own labeler code, drug listing and NDC for use in connection with the sale of GSK Supplied Product pursuant to the terms and conditions of this Agreement, and will promptly
provide such information to GSK as needed for inclusion on the GSK Supplied Product Labeling pursuant to Section 4.2(e). 
 (b) GSK
agrees, represents, and covenants that it shall, within five (5) Business Days after GSK’s receipt thereof, inform PAR and Spectrum of any adverse manufacturing notice to GSK (or its Affiliate) affecting the manufacture of GSK Supplied
Product including an FDA Form 483 warning letter, a consent decree, or other regulatory action. During the Term of this Agreement, GSK (or its Affiliate) will be responsible for any required reporting of matters regarding the manufacture, integrity,
and conformance to specifications of GSK Supplied Product for PAR to the FDA in accordance with Applicable Law; except for such reports that PAR is required to make under this Agreement or Applicable Law. GSK shall advise PAR within five
(5) Business Days after GSK’s receipt thereof of any occurrences or information that arise out of GSK’s manufacturing activities that have or could reasonably be expected to have adverse regulatory compliance or reporting consequences
concerning any of the GSK Supplied Product previously supplied to PAR. 
  

 23 

 Pursuant to 17 CFR 240.24b-2, confidential information has been omitted in places marked “[*
* *]” and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application filed with the Commission. 
  

 (c) GSK shall be responsible for handling and responding to any FDA or other governmental agency
inspections with respect to the manufacturing, packaging, and labeling of the GSK Supplied Product supplied to PAR and its Affiliates during the Term. GSK shall provide prompt notice of any governmental agency inspection related to the GSK Supplied
Product supplied to PAR, and shall use its reasonable efforts to within three (3) Business Days provide to PAR any information reasonably requested by PAR and all information requested by any governmental agency in connection with any such
governmental inspection (subject to any confidentiality or privilege restrictions or obligations to which GSK is subject). 
 (d) GSK shall
(subject to any confidentiality or privilege restrictions or obligations to which GSK is subject), as soon as is reasonably possible (but not later than five Business Days), notify PAR and Spectrum of (i) any pending or threatened litigation,
governmental investigation, proceeding or action involving any GSK Supplied Product or GSK’s (or its Affiliate’s or its suppliers or subcontractors) manufacturing facilities for GSK Supplied Product of which GSK becomes aware which might
reasonably adversely affect the supply of GSK Supplied Product to PAR and its Affiliates, and (ii) GSK shall use its reasonable efforts to notify PAR within twenty-four (24) hours (subject to any confidentiality or privilege restrictions
or obligations to which GSK is subject) of any defective, adulterated or misbranded GSK Supplied Product or of any information which may suggest that any GSK Supplied Product is or may be defective, adulterated or misbranded, or fails to meet the
specifications or to maintain the stability as indicated. For the avoidance of doubt, in the event a situation detailed in Section 5.7(b) were to suggest that any GSK Supplied Product is or may be defective, adulterated or misbranded, or fails
to meet the specifications or to maintain the stability as indicated, GSK shall use its reasonable efforts to notify PAR within twenty-four (24) hours (subject to any confidentiality or privilege restrictions or obligations to which GSK is
subject) of such situation. 
 Section 5.8 Business Operations. 
 (a) Product Complaints. Each Party (or its respective Affiliate) shall use its Commercially Reasonable Efforts to within two (2) Business Days
after receipt, but not longer than five (5) Business Days after receipt, provide the other Party (or its respective Affiliate) with written notice via facsimile of all complaints it receives that relate to, or arise from, GSK Supplied Product,
including those concerning manufacture, packaging, labeling, safety or efficacy of GSK Supplied Product. Notwithstanding the foregoing, each Party (or its respective Affiliate) shall use its Commercially Reasonable Efforts to within one
(1) Business Day after receipt provide the other Party (or its respective Affiliate) with written notice via facsimile of all reports of complaints of tampering or contamination that relate to, or arise from, GSK Supplied Product. GSK (or its
Affiliate) will investigate all complaints associated with the manufacture, packaging, labeling, safety or efficacy of GSK Supplied Product and provide a written summary to PAR (or its Affiliates). PAR (or its Affiliate) will investigate all other
complaints associated with the GSK Supplied Product and will provide a written summary to GSK (or its Affiliate). The responsible Party (or its Affiliate) also will provide a written response on each complaint to each complainant with a copy to the
other Party. The Parties (and their respective Affiliates) will reasonably cooperate with each other concerning the investigation of GSK Supplied Product complaints, including GSK’s (or its Affiliate’s) testing of GSK Supplied Product and
review of documents, and will provide such information as reasonably requested by the other Party (or its respective Affiliate) in connection with such investigations; provided however, that neither Party (nor their respective Affiliates) shall have
any obligation to provide its confidential business information to the other Party unless required by Applicable Law. The Parties (or their respective Affiliates) shall collaborate in developing procedures for providing information on GSK Supplied
Product complaints and inquiries and such 

  

 24 

 Pursuant to 17 CFR 240.24b-2, confidential information has been omitted in places marked “[*
* *]” and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application filed with the Commission. 
  

 
procedures will be outlined in the Quality Agreement. Nothing in this Section 5.8(a) shall affect the Parties’ (and their respective
Affiliates’) obligations with respect to pharmacovigilance reporting, as detailed in Section 4.4. 
 (b) Recalls, Withdrawals,
Field Alerts and Other Field Corrections. 
 (i) PAR shall promptly provide to GSK any information obtained by it or its Affiliates
suggesting that a recall, field alert, product withdrawal, or other field action relating to GSK Supplied Product (hereinafter “Product Action”) is or may be necessary (provided, PAR will use its Commercially Reasonable Efforts to
provide GSK with such information within twenty-four (24) hours after receipt by PAR). Further, [***] shall cooperate with [***] in obtaining any additional information that may bear upon whether to initiate a Product Action. The final decision
regarding whether to initiate a Product Action shall, however, rest with [***], after consultation with [***]. 
 (ii) GSK shall provide PAR
with prompt notice of any determination by GSK to initiate a Product Action, and PAR shall immediately comply with all reasonable applicable policies established by GSK from time to time and communicated to PAR in order to effectuate such Product
Action (provided, GSK will use its Commercially Reasonable Efforts to provide PAR with such determination within twenty-four (24) hours after such determination is made). Further, PAR shall undertake whatever assistance may be reasonably
requested by GSK to facilitate a Product Action, including but not limited to ensuring dissemination of information to its distributors and other customers and administering the retention, return and disposition of the applicable GSK Supplied
Product inventory in the applicable Territory. 
 (iii) The reasonable costs of any Product Action (including the reasonable costs of
notifying customers, the reasonable costs associated with [***] (and its Affiliates) customers, reasonable credits extended to [***] (and its Affiliates) customers as a result of the Product Action, and other reasonable costs incurred) shall be
borne by [***]; provided, however, [***] shall be responsible for all such reasonable costs associated with a Product Action to the extent resulting from any [***] (or any of its Affiliate’s) failure to comply with Applicable Law, this
Agreement or the Quality Agreement, or [***] (or any of its Affiliate’s) negligent or wrongful acts or failure to act which caused such Product Action, including [***] (or any of its Affiliate’s) negligent or wrongful handling (including
transportation), storage or possession of [***]. 
 Section 5.9 During the Term, the Parties shall notify each other as soon as
practicable of any circumstances of which they are aware which arise whereby the integrity and reputation of GSK Supplied Product or of the Parties are threatened by the unlawful activity of any Third Party in relation to GSK Supplied Product which
circumstances shall include, by way of illustration only, deliberate tampering with or contamination of GSK Supplied Product by any Third Party as a means of extorting payment from the Parties or another Third Party. In any such circumstances, the
Parties shall, to a reasonable extent, cooperate fully to limit any loss to the Parties. 
 Section 5.10 EXCEPT FOR THE EXPRESS
WARRANTIES AND REPRESENTATIONS AND COVENANTS CONTAINED IN THIS AGREEMENT, NEITHER PAR NOR GSK MAKES, AND EACH HEREBY EXPRESSLY DISCLAIMS, ANY WARRANTIES OR REPRESENTATIONS, EITHER EXPRESS OR IMPLIED, WHETHER IN FACT OR IN LAW, INCLUDING WITHOUT
LIMITATION IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR NON-INFRINGEMENT. 
  

 25 

 Pursuant to 17 CFR 240.24b-2, confidential information has been omitted in places marked “[*
* *]” and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application filed with the Commission. 
  

 ARTICLE VI - INTELLECTUAL PROPERTY AND CONFIDENTIAL INFORMATION 
 Section 6.1 Ownership of Pre-Existing Intellectual Property Rights. Any intellectual
property rights (including patents, patent applications, know-how, trade secrets, copyrights, trade dress, housemarks and trademarks) owned by either Party and their respective Affiliates prior to the Execution Date shall remain solely owned by such
Party (or their respective Affiliates, as applicable). Each of the Parties shall not during the Term, or at any time thereafter, represent or assert that it is the owner of any such intellectual property rights of the other Party (or their
respective Affiliates), whether or not such rights are registered. For the avoidance of doubt, the Parties agree that each of the Parties shall have no rights to use any trademark, housemark, copyright, or trade dress, of the other, and PAR
specifically has no right, directly or indirectly, to use the Imitrex® trademark for any
purpose, except as Applicable Law may permit a Third Party to use the trademark of another Person without a license, such as fair use references to the mark. Except as otherwise explicitly provided herein, no right, express or implied, is granted by
the Agreement to use in any manner the name “GSK,” “PAR,” “Glaxo Group Limited,” “Wellcome Manufacturing PTE Limited,” “Penn Labs”, “Penn Labs Inc.” or “GlaxoSmithKline” or the
name of any Affiliate of any Party. Without limiting the foregoing and as an example of use permitted by Applicable Law without a license, this Agreement does not prohibit PAR from stating in its Promotional Materials, in compliance with Applicable
Law, that the GSK Supplied Product is the generic equivalent of the applicable Imitrex®
injection branded product or that the GSK Supplied Product is manufactured by Penn Labs (a GlaxoSmithKline company) under the applicable NDA (and if PAR or its Affiliates use such a statement, PAR agrees to include the following trademark ownership
legend on such materials: “Imitrex® is a registered trademark of the GlaxoSmithKline
group of companies”). 
 Section 6.2 Confidential Information, Publicity and Publication. PAR and GSK each hereby recognize
and acknowledge that the other Party’s Confidential Information constitutes valuable and confidential information. Subject to other express provisions of this Agreement, the Parties each agree that as of the Execution Date and during the Term,
and for a period of [* * *] after the effective date of termination for any reason of this Agreement or the date of the expiration hereof: 
 (a) Except as may be explicitly permitted in this Agreement, the Parties shall not disclose, directly or indirectly, in any manner whatsoever to any Third Parties any Confidential Information received from the other Party (or its
Affiliates, as applicable) (the “Disclosing Party”) without first obtaining the written consent of the Disclosing Party, and the other Party (“Recipient”) shall keep confidential, all of the Disclosing Party’s
Confidential Information that is disclosed to Recipient. Recipient agrees to use the same level of care in safeguarding the Disclosing Party’s Confidential Information that Recipient uses with its own confidential information of a similar
nature, but in no event less than reasonable care. Recipient shall restrict disclosure of the Disclosing Party’s Confidential Information solely to those of its (or its Affiliate’s) employees or representatives having a need to know such
Confidential Information in order to accomplish the purposes of this Agreement. Each Party represents that its respective employees and representatives who receive the Confidential Information of the Disclosing Party are advised by such party of the
confidentiality obligations of this Agreement and shall maintain such Confidential Information in accordance with the confidentiality obligations set forth in this Article VI. 
  

 26 

 Pursuant to 17 CFR 240.24b-2, confidential information has been omitted in places marked “[*
* *]” and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application filed with the Commission. 
  

 (b) Recipient shall not use the Disclosing Party’s Confidential Information in any manner
whatsoever other than solely in connection with the exercise of its rights and the performance of its obligations under this Agreement. 
 (c) In the event Recipient is requested pursuant to, or required by, Applicable Law to disclose any of the Disclosing Party’s Confidential Information, it will notify the Disclosing Party promptly so that the Disclosing Party may seek
a protective order or other appropriate remedy or, in the Disclosing Party’s sole discretion, waive compliance with the confidentiality provisions of this Agreement. At the Disclosing Party’s expense, Recipient will co-operate in all
reasonable respects, in connection with any reasonable actions to be taken for the foregoing purpose. In any event, Recipient may furnish such Confidential Information as requested or required pursuant to Applicable Law (subject to any such
protective order or other appropriate remedy) without liability hereunder, provided that the Recipient furnishes only that portion of the Confidential Information which Recipient is advised by its counsel is legally required, and Recipient exercises
reasonable efforts to obtain reliable assurances that confidential treatment will be accorded the Disclosing Party’s Confidential Information. 
 (d) Upon the date of the expiration or termination of this Agreement for any reason, either Party may request in writing, and the other Party shall either: (i) promptly destroy all copies of the requesting Party’s Confidential
Information in the possession of the other Party and confirm such destruction in writing to the requesting Party; or (ii) promptly deliver to the requesting Party, at the requesting Party’s expense, all copies of such Confidential
Information in the possession of the other Party, provided, however, the other Party shall be permitted to retain one (1) copy of the requesting Party’s Confidential Information for the sole purpose of regulatory compliance. Additionally,
both Parties shall immediately cease all use of the other Party’s Confidential Information including, without limitation, removing all references to such Confidential Information from its analyses, compilations, studies or other documents. All
Confidential Information shall continue to be subject to the terms of this Agreement for the period set forth in this Section 6.2. 
 (e) Each Party represents and warrants to the other Party that it (or its respective Affiliates, as applicable) has, and shall have, all right, title, and ownership interest in and to its Confidential Information or it has, and shall have,
the right to disclose its Confidential Information to the other Party. Each Party may seek to enforce all rights and legal remedies available under this Article VI or by law, including, without limitation, injunctive relief, specific performance and
other equitable remedies in the event of a breach of the provisions of this Article VI by the other Party. 
 (f) Recipient shall cause its
Affiliates to observe the terms of this Article VI hereof, and shall be responsible for any breach of its provisions by any of its Affiliates. 
 (g) Notwithstanding the provisions of this Article VI, the Parties agree that nothing contained in this Article VI shall prevent Recipient in any way whatsoever from disclosing any of the Disclosing Party’s Confidential Information,
without obtaining Disclosing Party’s prior consent, to any Affiliate of Recipient or to any Third Party for the purposes of conducting their respective rights and obligations under this Agreement, provided such Third Party has undertaken an
obligation of confidentiality similar to such obligations contained in Article VI herein with respect to the Disclosing Party’s Confidential Information. 
 Section 6.3 Publicity. The Parties shall keep this Agreement and its provisions confidential using at least the level of care they use for their own proprietary information. As of the Execution Date

  

 27 

 Pursuant to 17 CFR 240.24b-2, confidential information has been omitted in places marked “[*
* *]” and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application filed with the Commission. 
  

 
and during the Term, no public announcement concerning the existence of, terms, or subject matter of this Agreement shall be made, either directly or
indirectly, by any Party, without first obtaining the approval of the other Party and agreement upon the nature and text of such public announcement which such agreement and approval shall not be unreasonably withheld, except, in the opinion of
legal counsel for the Party desiring to make such public announcement, as may be legally required by (i) the Applicable Law, including the United States Securities Act of 1933, as amended, the United States Securities Exchange Act of 1934, as
amended, (ii) the listing standards or agreements of any national or international securities exchange or The NASDAQ Stock Market or other similar laws of a governmental authority or agency, (iii) to respond to an inquiry of a governmental
authority or agency, or (iv) as may be required in a judicial, administrative or arbitration proceeding, in all instances seeking appropriate confidential treatment of this Agreement and the subject matter thereof and the Parties shall agree on
any redacted forms of the Agreement that are filed publicly, such agreement not to be unreasonably withheld or delayed. The Party desiring to make any such public announcement (including those which are legally required) shall inform the other Party
of the proposed announcement or disclosure in reasonably sufficient time prior to public release, which shall be not less than five (5) days (or such shorter period as the Parties may agree upon in writing, or such shorter period applicable to
those public announcements which are legally required)) prior to release of such proposed public announcement, and shall provide the other Party with a written copy thereof in order to allow such other Party to comment upon such public announcement.
Each Party agrees that it shall co-operate fully with the other with respect to all disclosures regarding this Agreement to any governmental or regulatory agencies, including requests for confidential treatment of proprietary information of either
Party included in any such disclosure. The Parties hereby agree that the press release attached hereto as Schedule 6.3 is approved for PAR and Spectrum to disseminate on or after the Execution Date in coordination with GSK’s corporate
communications department. 
 Section 6.4 Publication. As of the Execution Date and during the Term, PAR shall not submit for
written, electronic or oral publication any document, manuscript, abstract or the like which includes any data regarding GSK Supplied Product other than submissions required by Applicable Law, subject to Section 6.2(c). Any PAR contributions
shall be acknowledged in any GSK publication. 
 Section 6.5 Filing Requirements. As of the Execution Date: 
 (a) PAR and GSK each hereby represent, warrant and covenant, after consultation with its legal counsel, that the act of executing this Agreement does not
trigger or otherwise instigate any reporting, filing or other disclosure obligation on such Party’s (or any of its Affiliate’s) behalf pursuant to Applicable Law (excluding any U.S. Securities and Exchange Commission or Nasdaq Stock Market
reporting or disclosure obligations or requirements and filings under the Medicare Prescription Drug Improvement and Modernization Act of 2003); provided, however, notwithstanding Section 6.2(c), if the execution of this Agreement were to
trigger or otherwise instigate a reporting, filing or other disclosure obligation on such Party’s (or any of its Affiliate’s) behalf pursuant to Applicable Law, such Party shall immediately notify the other Party of such obligation, and
such Party further agrees not to make, file, or issue such report, filing or disclosure, directly or indirectly (except in connection with any U.S. Securities and Exchange Commission or Nasdaq Stock Market reporting or disclosure obligations or
requirements and filings under the Medicare Prescription Drug Improvement and Modernization Act of 2003), until the Parties, in good faith, agree upon the content, media and timing of such report, filing or disclosure. 
 (b) Notwithstanding anything to the contrary in this Article VI, as set forth in Title XI of the Medicare Prescription Drug Improvement and Modernization
Act (Subtitle B – Federal Trade 

  

 28 

 Pursuant to 17 CFR 240.24b-2, confidential information has been omitted in places marked “[*
* *]” and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application filed with the Commission. 
  

 
Commission Review) signed into law on December 8, 2003, each of the Parties shall submit this Agreement, the Settlement Agreement and the Stipulation of
Dismissal to the U.S. Federal Trade Commission (“Commission”) Bureau of Competition (“Bureau”) and the Assistant Attorney General within ten (10) business days of execution, and each Party shall present and (if
necessary) discuss or respond to questions regarding this Agreement with the Bureau or the Assistant Attorney General, provided such Party requests the Bureau and the Assistant Attorney General treat this Agreement, as confidential to the
extent legally permitted. 
 Section 6.6 Nothing in this Agreement shall be construed as preventing or in any way inhibiting either
Party from complying with Applicable Law governing activities and obligations undertaken pursuant to this Agreement, in any manner which it reasonably deems appropriate, including, for example, by disclosing to regulatory authorities confidential or
other information received from the other Party, subject to Section 6.2(c). 
 ARTICLE VII - TERM AND TERMINATION 
 Section 7.1 Term. This Agreement shall become effective as of the Effective Date and, unless sooner terminated pursuant to Section 7.2
below, shall automatically expire as of the Supply Termination Date, with the period between the Effective Date and such expiration or termination date being referred to as the “Term”. 
 Section 7.2 Termination. 
 (a) Termination for Breach. Each Party shall be entitled to terminate this Agreement by written notice to the other Party in the event that the other Party shall be in material default or material breach of any of its obligations
hereunder in any material respect, and shall fail to remedy any such default or breach within sixty (60) days after written notice thereof by the non-defaulting/non-breaching Party. If such default or breach is not corrected within the
foregoing sixty (60) day period, the non-breaching Party shall have the right to terminate this Agreement by giving written notice to the Party in default, provided the notice of termination is given within six (6) months of the default
and prior to correction of the default. 
 (b) Termination upon Bankruptcy. Either Party may terminate this Agreement if, at any time,
the other Party shall file in any court or agency pursuant to any statute or regulation of any state or country, a petition in bankruptcy or insolvency or for reorganization or for an arrangement or for the appointment of a receiver or trustee of
the Party or of its assets, or if the other Party proposes a written agreement of composition or extension of its debts, or if the other Party shall be served with an involuntary petition against it, filed in any insolvency proceeding, and such
petition shall not be dismissed with sixty (60) days after the filing thereof, or if the other Party shall propose or be a Party to any dissolution or liquidation, or if the other Party shall make an assignment for the benefit of creditors.

 (c) Notwithstanding anything to the contrary in this Section 7.2, concurrent with providing written notice to PAR of a default or
breach or GSK’s intent to terminate this Agreement, GSK shall provide the same written notice to Spectrum. Upon receipt of such notice, Spectrum or its designee shall, after the passage of thirty (30) days, have the right, but not the
obligation, to assume all of PAR’s rights and obligations hereunder, including the correction of any default or breach by PAR of its obligations hereunder, within the applicable cure period. 
  

 29 

 Pursuant to 17 CFR 240.24b-2, confidential information has been omitted in places marked “[*
* *]” and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application filed with the Commission. 
  

 (d) (i) If in the event after the first twelve (12) month period of the Supply Term the amount of the
applicable Supply Price paid by PAR to GSK on the GSK Supplied Product reaches a level that is at or below GSK’s Cost of Goods, GSK shall notify PAR of such situation in writing and provide PAR with a revised Supply Price that covers GSK’s
Cost of Goods (but is not in excess of [* * *] percent ([* * *]%) over GSK’s Cost of Goods. PAR shall then have the right, upon giving GSK two (2) months prior written notice (with such notice referencing this Section 7.2(d) as the
reason for termination), to either terminate this Agreement or agree to remit to GSK such revised Supply Price. 
 (ii) Upon receipt of the
written notice reference in subsection (i) above, PAR shall have the right, within thirty (30) days after receipt of such notice, to have an independent certified public accountant, satisfactory to GSK in GSK’s reasonable discretion, (the
“COGS Auditor”) inspect GSK’s records relating to its Cost of Goods for the GSK Supplied Product for the four (4) months preceding such notice, for the sole purpose of determining the accuracy of GSK’s assertion that the
Supply Price paid by PAR to GSK on such GSK Supplied Product has reached a level that is at or below GSK’s Cost of Goods for such GSK Supplied Product and that the increase in the new Supply Price reflects only the increase in GSK’s Cost
of Goods (and is within the foregoing [* * *] percent ([* * *]%) limit). GSK shall permit the COGS Auditor to have confidential reasonable access during normal business hours to such records of GSK as may be reasonably necessary to verify such GSK
statement. The COGS Auditor shall reach its conclusion as quickly as possible, but in no event more than a period of thirty (30) days, and notify the Parties of its conclusion in writing. In the event the COGS Auditor concludes that GSK’s
statement was accurate, PAR shall either terminate this Agreement or agree to remit to GSK such revised Supply Price pursuant to Subsection (i) above. In the event the COGS Auditor determines GSK’s statement was inaccurate, GSK shall not be
entitled to such increased Supply Price and the previous Supply Price shall remain applicable. The reasonable fees and expenses charged by the COGS Auditor shall be paid by PAR unless the COGS Auditor determines GSK’s statement was inaccurate,
in which event such reasonable fees and expenses shall be paid by GSK. In no event shall GSK be obligated to reveal its Cost of Goods figures to PAR and such figures shall remain GSK Confidential Information, and the COGS Auditor shall report, in
confidence, to PAR only its conclusions as to whether such GSK statement and revised Supply Price was accurate or inaccurate. GSK shall use its commercially reasonable efforts to keep the Cost of Goods below the Supply Price. 
 (e) This Agreement may be terminated at any time pursuant to the mutual written consent of GSK, PAR and Spectrum. 
 (f) This Agreement may be terminated and become null and void as of the Execution Date pursuant to the provisions of the Settlement Agreement.

 Section 7.3 Effect of Termination. 
 (a) Upon termination or expiration of this Agreement, each Party shall have the right to retain any sums already due and paid by the other Party hereunder, and each Party shall immediately pay to the other Party all
sums accrued hereunder which are then due, including any and all Net Sales Split, Supply Price [***]. 
 (b) Notwithstanding anything to the
contrary in this Section 7.3 or any other Section of this Agreement, termination or expiration of this Agreement in accordance with the provisions hereof and, the operation of any provisions of this Section 7.3, shall not in any way limit
the Parties’ remedies that may be otherwise available to them in law or equity. 
  

 30 

 Pursuant to 17 CFR 240.24b-2, confidential information has been omitted in places marked “[*
* *]” and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application filed with the Commission. 
  

 (c) Termination or expiration of this Agreement in its entirety shall terminate all outstanding
obligations and liabilities between the Parties arising from this Agreement except those described in: 
 (i) Section 3.1, 3.2(b);

 (ii) Section 3.8 (with respect to the records retention obligation for the period set forth in Section 5.6); 
 (iii) Section 3.9 (for the [* * *] ([* * *]) year post-termination/expiration period set forth therein); 
 (iv) Section 5.6 (for the applicable record retention period set forth therein); 
 (v) Article VI (for the [* * *] ([* * *]) year post-termination/expiration period set forth therein); 
 (vi) Sections 4.2(a)(iii) and (b), 5.8(b), 5.9, 7.3, 8.1 through 8.3, Article IX, and Article X; and 
 (vii) Section 8.4 (for the [* * *] ([* * *]) year post-termination/expiration period set forth therein) 
 as well as those under any other provisions which by their nature are intended to survive any such termination or expiration, shall survive and continue to be
enforceable. 
 (d) In the event GSK terminates this Agreement pursuant to Section 7.2(a) due to a PAR breach PAR shall reimburse GSK
for all reasonable costs associated with any obsolete inventory and other materials bearing PAR’s trademarks or artwork (GSK Supplied Product, Labels, packaging, tooling, etc.) resulting from the termination of this Agreement, provided GSK uses
its reasonable efforts to mitigate the costs associated with such obsolete materials. 
 (e) In the event PAR terminates this Agreement
pursuant to Section 7.2(a) due to a material GSK breach or a material GSK default, [* * *]. 
 ARTICLE VIII - INDEMNIFICATION,
INSURANCE AND DISPUTE RESOLUTION 
 Section 8.1. Indemnification. 
 (a) GSK Indemnification Obligations. GSK shall indemnify, defend and hold PAR, its Affiliates, and its and their officers, directors, trustees,
agents and employees (individually and/or collectively referred to herein as an “PAR Party”) harmless from and against any and all losses, liabilities, damages (inclusive of indirect or incidental (but excluding special,
consequential or punitive) losses or 

  

 31 

 Pursuant to 17 CFR 240.24b-2, confidential information has been omitted in places marked “[*
* *]” and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application filed with the Commission. 
  

 
damages), fees (but only reasonable attorneys fees and expenses and costs of litigation pertaining to such PAR Claim), and expenses paid or payable by PAR or
a PAR Party to a Third Party (collectively, “PAR Losses”) to the extent that such PAR Losses result from or arise in connection with a claim, suit or other proceeding made or brought by a Third Party against PAR or a PAR Party (a
“PAR Claim”) based on, resulting from, or arising in connection with: 
 (i) the breach of any obligation (including the
failure by GSK to supply the GSK Supplied Product pursuant to the terms of this Agreement), covenant, agreement, representation or warranty of GSK or a GSK Party contained in this Agreement; 
 (ii) any violation of Applicable Law by GSK, or a GSK Party, in connection with the performance of GSK’s or its Affiliates’ obligations under
this Agreement; or 
 (iii) [***] 
 provided, however, that GSK shall not be obligated to indemnify, defend or hold harmless PAR or a PAR Party under this Section from any PAR Claim or for any PAR Losses incurred by PAR or a PAR Party to the extent arising out of or
attributable to (A) a breach by PAR, or any PAR Party of any obligation, covenant, agreement, representation or warranty of PAR, or any PAR Party contained in this Agreement, or (B) any act or omission by PAR or a PAR Party, which
constitutes negligence, recklessness, gross negligence, or willful misconduct on the party of PAR or a PAR Party or (C) [***] to the extent PAR is responsible for indemnifying, defending and holding GSK and GSK Parties harmless for such [***]
as set forth in Section 8.1(b). 
 (b) PAR Indemnification Obligations. PAR shall indemnify, defend and hold GSK and their
respective Affiliates, and its and their employees, agents, officers, and directors (individually and/or collectively referred to hereinafter as a “GSK Party”) harmless from and against any and all losses, liabilities, damages
(inclusive of indirect or incidental (but excluding special, consequential or punitive) losses or damages), fees (but only reasonable attorneys fees and expenses and costs of litigation pertaining to such GSK Claim), and expenses paid or payable by
GSK or a GSK Party to a Third Party (collectively, “GSK Losses”) to the extent that such GSK Losses result from or arise in connection with a claim, suit or other proceeding made or brought by a Third Party against GSK or a GSK
Party (a “GSK Claim”) based on, resulting from, or arising in connection with: 
 (i) the breach of any obligation,
covenant, agreement, representation or warranty of PAR, or a PAR Party contained in this Agreement; 
 (ii) any act or omission by PAR, or a
PAR Party which renders a GSK Supplied Product defective or unreasonably dangerous, creates or contributes to a [***], or constitutes recklessness, gross negligence, or willful misconduct on the part of PAR or a PAR Party, or results from any PAR or
PAR Party’s failure to meet GSK’s applicable product handling, shipping, or storage specifications that have been provided by GSK to PAR in writing reasonably in advance of the effectiveness thereof; 
 (iii) any violation of Applicable Law by PAR or a PAR Party in connection with the performance of PAR’s or its Affiliates’ obligations under
this Agreement (including any distribution, marketing, promotion, detailing, and sale of GSK Supplied Product by PAR in violation of Applicable Law); 
  

 32 

 Pursuant to 17 CFR 240.24b-2, confidential information has been omitted in places marked “[*
* *]” and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application filed with the Commission. 
  

 (iv) [***] 
 provided, however, that PAR shall not be obligated to indemnify, defend or hold harmless GSK or a GSK Party from any GSK Claim or for any GSK Loss incurred by GSK or a GSK Party to the extent arising out of, or attributable to,
(A) a breach by GSK or any GSK Party of any obligation, covenant, agreement, representation or warranty of GSK or a GSK Party contained in this Agreement; or (B) any act or omission by GSK, or a GSK Party, which constitutes negligence,
recklessness, gross negligence, or willful misconduct on the part of GSK, or a GSK Party, or (C) [***] to the extent GSK is responsible for indemnifying, defending and holding PAR and PAR Parties harmless for such [***] as set forth in
Section 8.1(a). 
 (c) Indemnification Procedures. 
 (i) Each indemnified Party shall notify the indemnifying Party in writing (and in reasonable detail) of the Claim within ten (10) business days
after receipt by such indemnified Party of notice of the GSK Claim or PAR Claim, as the case may be, or otherwise becoming aware of the existence or threatened existence thereof (such GSK Claim or PAR Claim being referred to as a
“Claim”). Failure to give such notice shall not constitute a defense, in whole or in part, to any claim by an indemnified Party hereunder except to the extent the rights of the indemnifying Party are materially prejudiced by such
failure to give notice. The Indemnifying Party shall notify the indemnified Party of its intentions as to defense of the Claim or potential Claim in writing within ten (10) Business Days after receipt of notice of the Claim. If the indemnifying
Party assumes the defense of a Claim against an indemnified Party, an indemnifying Party shall have no obligation or liability under this Article VIII as to any Claim for which settlement or compromise of such Claim or an offer of settlement or
compromise of such Claim is made by an indemnified Party without the prior written consent of the indemnifying Party, which consent shall not be unreasonably withheld. 
 (ii) The indemnifying Party shall assume exclusive control of the defense and settlement (including all decisions relating to litigation, defense and appeal) of any such Claim (so long as it has confirmed its
indemnification obligation responsibility to such indemnified Party under this Section 8.1(c) with respect to a given Claim); provided, however, that the indemnifying Party may not settle such Claim in any manner that would
require payment by the indemnified Party, or would materially adversely affect the rights granted to the indemnified Party hereunder, or would materially conflict with the terms of this Agreement, or adversely affect the Products in or outside the
Territory, without first obtaining the indemnified Party’s prior written consent, which consent shall not be unreasonably withheld. 
 (iii) The indemnified Party shall reasonably cooperate with the indemnifying Party in its defense of the Claim (including, without limitation, making documents and records available for review and copying and making persons within its
control available for pertinent testimony in accordance with the confidentiality provisions of Article VI, and neither Party shall be required to divulge privileged material to the other) at the indemnifying Party’s expense. If the indemnifying
Party assumes defense of the Claim, an indemnified Party may participate in, but not control, the defense of such Claim 

  

 33 

 Pursuant to 17 CFR 240.24b-2, confidential information has been omitted in places marked “[*
* *]” and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application filed with the Commission. 
  

 
using attorneys of its choice and at its sole cost and expense, with such cost and expense not being covered by the indemnifying Party. If an indemnifying
Party does not agree to assume the defense of the Claim asserted against the indemnified Party (or does not give notice that it is assuming such defense), or if the indemnifying Party assumes the defense of the Claim in accordance with
Section 8.1(c) yet fails to defend or take other reasonable, timely action, in response to such Claim asserted against the indemnified Party, the indemnified Party shall have the right to defend or take other reasonable action to defend its
interests in such proceedings, and shall have the right to litigate, settle or otherwise dispose of any such Claim; provided, however, that no Party shall have the right to settle a Claim in a manner that would adversely affect the
rights granted to the other Party hereunder, or would materially conflict with this Agreement, or would require a payment by the Party, or adversely affect the Products in or outside the Territory, without the prior written consent of the Party
entitled to control the defense of such Claim. 
 Section 8.2 Dispute Resolution. 
 (a) Negotiation. Except as set forth in Section 4.2(h) with respect to a disagreement regarding the rejection of GSK Supplied Product or as to
a dispute arising out of the provisions of Section 4.2(a)(iii), if a dispute or controversy regarding any right or obligation under this Agreement arises between the Parties, the Parties will seek to resolve such dispute or controversy or
failure to agree by good faith negotiation between senior management representatives of the Parties, to be commenced promptly after such dispute or controversy or failure to agree arises. If such dispute or controversy or failure to agree is not
resolved by such negotiation within thirty (30) days after written notice by one Party to the other, each Party shall be free to pursue any other course of action available to such Party. 
 (b) With the exception of disputes arising out of the provisions of Section 4.2(a)(iii), the provisions of this Section 8.2 shall not restrict
either Party’s rights to seek preliminary injunctive or other equitable relief from any court having jurisdiction, or to take action as such Party deems necessary to preserve its rights and to protect its interests. 
 (c) With respect solely to disputes arising out of the provisions of Section 4.2(a)(iii), such disputes will be settled through binding arbitration,
if initiated by one of the Parties. The place of the arbitration shall be New York, NY, U.S.A. (unless the Parties agree otherwise) and the arbitration shall be in the English language and conducted in accordance with the American Arbitration
Association (“AAA Rules”) on a expedited basis. The arbitration will be heard and determined by one (1) arbitrator, who will be jointly selected by GSK and PAR. If, within thirty (30) days following the date upon which a claim is
received by the respondent, the Parties cannot agree on a single arbitrator, the arbitration will be heard and determined by three (3) arbitrators, with one arbitrator being appointed by each Party and the third arbitrator being selected by the
two Party-appointed arbitrators. If either Party fails to select an arbitrator, or if the Party-appointed arbitrators cannot agree on a third arbitrator within sixty (60) days of the respondent receiving the claim, such arbitrator will be
appointed by the AAA according to the AAA Rules. The arbitration award so given will be binding upon the Parties, accompanied by a reasoned opinion in writing (in English), and the judgment on the award may be entered in any court having
jurisdiction thereof. Each Party will bear its own costs and expenses (including its attorney’s fees) associated with any arbitration initiated under this section, and each Party will bear an equal share of the arbitrators’ and
administrative fees associated with any arbitration initiated under this section. 
 Section 8.3. EXCEPT [***], IN NO EVENT SHALL EITHER
PARTY, ITS DIRECTORS, TRUSTEES, OFFICERS, EMPLOYEES, AGENTS OR AFFILIATES BE LIABLE TO THE OTHER PARTY FOR ANY 

  

 34 

 Pursuant to 17 CFR 240.24b-2, confidential information has been omitted in places marked “[*
* *]” and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application filed with the Commission. 
  

 
INDIRECT, INCIDENTAL, PUNITIVE, SPECIAL, EXEMPLARY OR CONSEQUENTIAL DAMAGES, WHETHER BASED UPON A CLAIM OR ACTION OF CONTRACT, WARRANTY, NEGLIGENCE, STRICT
LIABILITY OR OTHER TORT, A PRODUCT CLAIM, OR OTHERWISE ARISING OUT OF OR RELATED TO THIS AGREEMENT. 
 Section 8.4. Insurance.

 (a) For the Term, and for a period of [***] after the expiration of this Agreement or the earlier termination thereof, PAR shall maintain
at its sole cost and expense, product liability and other insurance for itself in amounts, respectively, which are reasonable and customary in the United States pharmaceutical industry for companies of comparable size and activities at the
respective place of business of PAR, provided in no event shall the product liability insurance amounts be less than [* * *] U.S. Dollars (U.S. $[* * *]) per occurrence (or claim) and [* * *] U.S. Dollars (U.S. $[* * *]) in the aggregate limit of
liability per year. Such insurance shall insure against all liability, including personal injury, product liability, physical injury, clinical development liabilities, or property damage arising out of the development, manufacture (including
packaging and labeling), sale, distribution, or marketing of GSK Supplied Products. PAR shall provide written proof of the existence of such insurance to GSK upon request. 
 (b) GSK hereby represents that it is self-insured for product liability and general liability, and that it has and will maintain such coverage for the
Term and for a period of [***] years after the expiration of this Agreement or the earlier termination thereof. Such self-insurance is in an amount which is reasonable and customary in the United States pharmaceutical industry for companies of
comparable size and activities at the respective place of business of GSK. GSK shall provide a written statement of the existence of such insurance to PAR upon request. 
 ARTICLE IX MISCELLANEOUS 
 Section 9.1 Assignment. Upon thirty (30) days advance
written notice provided jointly by PAR and Spectrum to GSK, the rights and obligations of PAR under this Agreement with respect to the GSK Supplied Products that are subject to such written notice shall be assigned to Spectrum or to such other Third
Party designated by Spectrum; provided that Spectrum or such other Third Party agrees to be responsible for the full and complete performance of all of PAR’s obligations under the terms and conditions of this Agreement. In the event of such a
foregoing assignment of this Agreement to Spectrum or a Third Party, [***]. Except as set forth in this Section 10.1, this Agreement may not be assigned by either Party without the prior written consent of the other Party; provided,
however, that each Party shall have the right to assign its rights and obligations under this Agreement to any Third Party successor pursuant to a merger, consolidation, or sale of all or substantially all of (i) its entire business or
(ii) its pharmaceutical business; or (iii) the assets associated with this Agreement; or (iv) the manufacturing facility in which the GSK Supplied Product is manufactured. In addition, each Party may assign, to any of its Affiliates,
its rights and obligations of such Party under this Agreement, provided that such Affiliate is fully capable of fulfilling the assigned rights and obligations. In no event shall such assignment to an Affiliate (or pursuant to clauses
(i) through (iv) above) be deemed to relieve the assigning Party of its liabilities or 

  

 35 

 Pursuant to 17 CFR 240.24b-2, confidential information has been omitted in places marked “[*
* *]” and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application filed with the Commission. 
  

 
obligations to the other Party under this Agreement, and the assigning Party expressly acknowledges and agrees that it shall remain fully and unconditionally
obligated and responsible for the full and complete performance of all of its obligations under the terms and conditions of this Agreement. The limited rights of assignment permitted in this Section 9.1, shall in no way limit GSK’s right
to terminate this Agreement pursuant to Section 7.2(d). 
 Section 9.2 Counterparts. This Agreement may be executed in any
number of counterparts, each of which shall be deemed an original but all of which together shall constitute one and the same instrument. 
 Section 9.3 Force Majeure. [***], neither Party shall lose any rights hereunder or be liable to the other Party for damages or losses on account of failure of performance by the defaulting Party if the failure is occasioned by
government action, war, terrorism, fire, explosion, flood, strike, lockout, embargo, shortage of materials or utilities, vendor failure to supply, act of God, or any other cause beyond the control and without the fault or negligence of the
defaulting Party, provided that the Party claiming force majeure has exerted all reasonable efforts to avoid or remedy such force majeure; provided, however, that in no event shall a Party be required to settle any labor dispute or disturbance. Such
excuse shall continue as long as the condition preventing the performance continues. Upon cessation of such condition, the affected Party shall promptly resume performance hereunder. Each Party agrees to give the other Party prompt written notice of
the occurrence of any such condition, the nature thereof, and the extent to which the affected Party will be unable to perform its obligations hereunder. Each Party further agrees to use all reasonable efforts to correct the condition as quickly as
possible and to give the other Party prompt written notice when it is again fully able to perform its obligations. 
 Section 9.4
Further Assurances. Each Party hereto agrees to execute, acknowledge and deliver such further instruments and do all such further acts as may be necessary or appropriate to carry out the purposes and intent of this Agreement. 
 Section 9.5 Modification. No waiver, alteration or modification of any of the provisions hereof shall be binding unless made in writing and
signed by the Parties by their respective officers thereunto duly authorized. 
 Section 9.6 Independent Contractors. The Parties
are independent contractors and this Agreement shall not constitute or give rise to an employer-employee, agency, partnership or joint venture relationship among the Parties and each Party’s performance hereunder is that of a separate,
independent entity. 
 Section 9.7 Governing Law. This Agreement shall be governed by and construed in accordance with the laws
of the State of New York, United States without regard to its conflicts of laws principles. 
 Section 9.8 Language. This
Agreement, and any amendments or modifications thereto, shall be executed in the English language. No translation, if any, of this Agreement into any other language shall be of any force or effect in the interpretation of this Agreement or in
determination of the intent of either of the Parties hereto. 
  

 36 

 Pursuant to 17 CFR 240.24b-2, confidential information has been omitted in places marked “[*
* *]” and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application filed with the Commission. 
  

 Section 9.9 Article Headings. The Article headings are placed herein merely as a matter
of convenience and shall not affect the construction or interpretation of any of the provisions of this Agreement. 
 Section 9.10
Notices. Notices required or permitted under this Agreement shall be in writing and sent by prepaid registered or certified air mail or by overnight express mail (e.g., FedEx), or by telefacsimile confirmed by prepaid registered or certified
air mail letter or by overnight express mail (e.g., FedEx), (failure of such confirmation shall not affect the validity of such notice by telefacsimile to the extent the receipt of such notice is confirmed by the act of the receiving Party (e.g., a
telefacsimile of the receiving Party submitting its receipt of such notice)) and shall be deemed to have been properly served to the addressee upon receipt of such written communication, to the following addresses of the Parties: 
 If to PAR: 
 PAR
Pharmaceutical Companies, Inc. 
 300 Tice Boulevard, 3rd Floor 
 Woodcliff Lake, NJ 07677 
 Attention: General Counsel 
 Facsimile: (201) 802-4223 
 If to GSK: 
 SmithKline Beecham Corporation (d/b/a GlaxoSmithKline) 
 One Franklin Plaza (Mail Code FP 2230) 
 P.O. Box 7929 
 Philadelphia, Pennsylvania 19101, United States 
 Attention: [***] 
 Fax: [***] 
 and: 
 SmithKline Beecham Corporation (d/b/a GlaxoSmithKline) 
 One Franklin Plaza (Mail Code FP
2230) 
 P.O. Box 7929 
 Philadelphia, Pennsylvania 19101, United States 
 Attention: [***] 
 [***] 
 Facsimile: [***] 
 Section 9.11 Third Parties. None of the provisions of this Agreement shall be for the benefit of or
enforceable by any Third Party, except for Spectrum, which shall be a third party beneficiary to this Agreement. 
 Section 9.12
Waiver. The waiver by either Party of a breach or a default of any provision of this Agreement by the other Party shall not be construed as a waiver of any succeeding breach of the same or any other provision, nor shall any delay or omission
on the part of either Party to exercise or avail itself of any right, power or privilege that it has or may have hereunder operate as a waiver of any right, power or privilege by such Party. 
  

 37 

 Pursuant to 17 CFR 240.24b-2, confidential information has been omitted in places marked “[*
* *]” and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application filed with the Commission. 
  

 Section 9.13 Severability. If any part of this Agreement is declared invalid by any
legally governing authority having jurisdiction over either Party, then such declaration shall not affect the remainder of the Agreement and the Parties shall revise the invalidated part in a manner that will render such provision valid without
impairing the Parties’ original intent. 
 Section 9.14 Entire Agreement. This Agreement, including the Settlement Agreement
and the ancillary agreements referenced herein, constitutes the entire agreement between the Parties relating to the subject matter hereof and supersedes all previous writings and understandings. 
 Section 9.15 International Sale of Goods Act. The Parties acknowledge and agree that the International Sale of Goods Act and the United
Nations Convention on Contracts for the International Sale of Goods have no application to this Agreement. 
 [signatures appear on the
following page] 
  

 38 

 Pursuant to 17 CFR 240.24b-2, confidential information has been omitted in places marked “[*
* *]” and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application filed with the Commission. 
  

 IN WITNESS WHEREOF, the Parties hereto have caused this Supply and Distribution Agreement to be executed as of the
Execution Date by their duly authorized representatives. 
 GLAXO WELLCOME MANUFACTURING PTE LIMITED 
  

			
	By:	 	 /s/    Lai-Kuen Goh

		
	Title:	 	Finance Director

 Pursuant to 17 CFR 240.24b-2, confidential information has been omitted in places marked “[*
* *]” and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application filed with the Commission. 
  

 GLAXO GROUP LIMITED 
  

			
	By:	 	 /s/    Charles Dadswell

		
	Title:	 	Vice President

 Pursuant to 17 CFR 240.24b-2, confidential information has been omitted in places marked “[*
* *]” and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application filed with the Commission. 
  

 PAR PHARMACEUTICAL, INC. 
  

			
	By:	 	 /s/ Paul Campanelli

		
	Title:	 	 SVP, Business Development & Licensing

		
		 	(on behalf of Patrick G. LePore, President and Chief Executive Officer )

  

 Pursuant to 17 CFR 240.24b-2, confidential information has been omitted in places marked “[*
* *]” and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application filed with the Commission. 
  

 Acknowledged and Agreed: 
 SPECTRUM PHARMACEUTICALS, INC. 
  

			
	By:	 	 /s/ Rajesh C. Shrotriya, M.D.

		
	Title:	 	 Chairman, CEO and President

 Pursuant to 17 CFR 240.24b-2, confidential information has been omitted in places marked “[*
* *]” and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application filed with the Commission. 
  

 SCHEDULE 3.4(a) 
 GSK Supplied Product Supply Price 
 GSK Supplied Products: 
  

			
	 Product
	 	 USD per Unit

	 [* * *]
	 	[* * *]

 Pursuant to 17 CFR 240.24b-2, confidential information has been omitted in places marked “[*
* *]” and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application filed with the Commission. 
  

 SCHEDULE 3.4(c) 
 Form of Trading Services Agreement 
 [DATE] 
 RE: Agreement dated [XXX] between Glaxo Group Limited and Glaxo Wellcome Manufacturing PTE Limited and [PAR Entity] for the supply of Generic Injection Products and Generic [* * *] Products in the
Territory (“the Principal Contract”). 
 Reference is made to the Principal Contract. Words and expressions defined or interpreted in the
Principal Contract shall have the same meanings when used or interpreted in this Agreement. This Agreement records the terms on which GlaxoSmithKline Trading Services Limited as Affiliate and Nominated Supplier shall sell forms of generic
Sumatriptan injection products (defined in the Principal Contract as “GSK Supplied Product”) to [PAR Pharmaceutical, Inc.] (“PAR”) 
  

	1.	The terms of the sale of the GSK Supplied Product to PAR are as follows: 

  

	 	•	 	 Supply Prices and Net Sales Split – as set out in the Schedule A attached; 

  

	 	•	 	 [***] (Incoterms 2000); and 

  

	 	•	 	 Payment within forty-five (45) days after date of invoice, as per the Principal Contract in USD by electronic transfer to the 

 following Bank Account: 
  

  

  

  

	2.	The terms and conditions of the Principal Contract shall in all other respects govern the relationship between GlaxoSmithKline Trading Services Limited and PAR, so far as applicable
to the sale and purchase of the GSK Supplied Products under this Agreement. 

  

	3.	Any Agreements previously entered into between GlaxoSmithKline Trading Services Limited and PAR, with respect to the supply of the GSK Supplied Products by GlaxoSmithKline Trading
Services Limited to PAR, are superseded and replaced by this Agreement. 

  

	4.	This Agreement shall terminate automatically in the event that the Principal Contract terminates for any reason. Any amounts due to GlaxoSmithKline Trading Services Limited prior to
any such termination shall continue to be payable to GlaxoSmithKline Trading Services Limited not withstanding any such termination. 

  

	5.	This Agreement shall be governed by and construed in accordance with the laws in effect in the State of New York, without regard to its conflicts of laws principles.

 Pursuant to 17 CFR 240.24b-2, confidential information has been omitted in places marked “[*
* *]” and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application filed with the Commission. 
  

																													
	For and on behalf of	  		  		  		  		  		  		  		  		  		  		  		  		  		  	For and on behalf of
															
	GLAXOSMITHKLINE TRADING SERVICES LTD	  		  		  		  		  		  		  		  		  		  		  		  		  		  	PAR PHARMACEUTICAL, INC.
															
	  
	  		  		  		  		  		  		  		  		  		  		  		  		  		  	  

	Signature	  		  		  		  		  		  		  		  		  		  		  		  		  		  	Signature
															
	  
	  		  		  		  		  		  		  		  		  		  		  		  		  		  	  

	Name	  		  		  		  		  		  		  		  		  		  		  		  		  		  	Name
															
	  
	  		  		  		  		  		  		  		  		  		  		  		  		  		  	  

	Position	  		  		  		  		  		  		  		  		  		  		  		  		  		  	Position

 Pursuant to 17 CFR 240.24b-2, confidential information has been omitted in places marked “[*
* *]” and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application filed with the Commission. 
  

 SCHEDULE 4.2(b) 
 Form of Quality Agreement 
 Sent to PAR on November 9, 2006 

 Pursuant to 17 CFR 240.24b-2, confidential information has been omitted in places marked “[*
* *]” and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application filed with the Commission. 
  

 SCHEDULE 4.2(b)(iii) 
 GSK Supplied Product and Its Specifications 
 In the event GSK were to revise the formulation
or specifications for its branded Imitrex®
[* * *] product in the Territory, GSK may, at its discretion, switch the formulation or specifications of GSK Supplied Product to match that of the revised branded Imitrex® [* * *] formulation or specifications, provided GSK shall ensure that such
switch shall not disrupt the supply of GSK Supplied Product to PAR. Any change to specifications will be managed according to the Quality Agreement and such specifications will be maintained accordingly in that document. 
 Specification for Sumatriptan Succinate Injection [* * *] ([* * *]and [* * *]) 
  

			
	 Test
	    	 Specification

	 [* * *]
	    	[* * *]

 Pursuant to 17 CFR 240.24b-2, confidential information has been omitted in places marked “[*
* *]” and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application filed with the Commission. 
  

 SCHEDULE 4.2(c) 
 GSK Supplied Product and Initial PAR Estimate 
 I. GSK Supplied Product (aside from the Initial Quantity)
shall be delivered to PAR (per Section 4.2(c)) with the following minimum remaining shelf life: 
 (a) For the Generic Injection Product,
[* * *]; and 
 (b) For the Generic [* * *] Product, [* * *]; and 
 (c) The foregoing shall not be applicable to any GSK Supplied Product held for quality assurance purposes. 
 II. All GSK Supplied Product must be ordered in full batch increments, either individually in full increments of minimum quantity order or concurrently at the
minimum and incremental order quantities to consume the full batch quantity (as set forth on Schedule 4.2(d)). 

 Pursuant to 17 CFR 240.24b-2, confidential information has been omitted in places marked “[*
* *]” and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application filed with the Commission. 
  

 III. [* * *] 
 [* * *] 

 Pursuant to 17 CFR 240.24b-2, confidential information has been omitted in places marked “[*
* *]” and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application filed with the Commission. 
  

 [* * *] 
 [* * *] 

 Pursuant to 17 CFR 240.24b-2, confidential information has been omitted in places marked “[*
* *]” and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application filed with the Commission. 
  

 SCHEDULE 4.2(d) 
 Initial Quantity 
 Delivery Timing: 
 The Initial Quantity of GSK Supplied Product shall be delivered to PAR pursuant to Section 4.2(d). 
 Initial
Quantity: 
  

									
	 [* * *]
	  	[* * *]	  	[* * *]	  	[* * *]	  	[* * *]

 All GSK Supplied Product must be ordered in full batch increments, either individually in full increments of
minimum order quantity or concurrently at the incremental order quantities to consume a full batch. 
 *[* * *] presentations must be ordered in
full batch increments, either individually in full increments of minimum order quantity or concurrently at the incremental order quantities to consume a full batch. 
 **[* * *] presentations must be ordered in full batch increments, either individually in full increments of minimum order quantity or concurrently at the incremental order quantities to consume a full batch.

 Pursuant to 17 CFR 240.24b-2, confidential information has been omitted in places marked “[*
* *]” and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application filed with the Commission. 
  

 SCHEDULE 4.4 
 Form of Pharmacovigilance Agreement 
 PHARMACOVIGILANCE AGREEMENT 
 Between 
 Glaxo Wellcome Manufacturing PTE
Limited] 
 and 
 [PAR
Pharmaceutical, Inc.] 
 for Generic Injection Product and Generic [* * *] Product 
 Effective date of this agreement: [INSERT DATE] 
  

	1.	Background 

 Glaxo Wellcome Manufacturing PTE Limited (collectively
hereinafter “GSK”) and PAR Pharmaceutical, Inc. (hereinafter “PAR”) entered into a Supply and Distribution Agreement, regarding Generic Injection Product and the Generic [* * *] Product (hereinafter
“Product”) dated as of [insert date] (hereinafter the “Main Agreement”). Hereinafter GSK and PAR may be referred to as the “Party” in the singular and “Parties” in the plural. 
 This Pharmacovigilance Agreement (the “Agreement”) has been prepared in accordance with Section 4.4 of the Main Agreement. 
 This Agreement describes the procedures, time frames and responsibilities that the Pharmacovigilance Departments of all Parties will employ to assure compliance with the
applicable laws and regulations pertaining to safety reporting and its related activities. 
 Title 21 of the Code of Federal Regulations will be adhered to
in relation to any applicable U.S. reporting requirements. 
  

	 	•	 	 21 CFR § 314.80 (Post-marketing Reporting of Adverse Drug Experiences) 

 Pursuant to 17 CFR 240.24b-2, confidential information has been omitted in places marked “[*
* *]” and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application filed with the Commission. 
  

	2.	Definitions 

 Adverse Event (AE) 
 Any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered
related to the medicinal product. 
 An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or
disease (new or exacerbated) temporally associated with the use of a medicinal product. For marketed medicinal products, this also includes failure to produce expected benefits (i.e. lack of efficacy), abuse or misuse. 
 Pregnancy 
 Pregnancy is not regarded as an AE per se. Reports of
pregnancy involving an AE will be handled as AE reports. Reports of pregnancy that involve no AE will be handled as pregnancy reports and exchanged as specified in this agreement. 
 “Product(s)” 
 Product shall mean the Generic Injection Product and the Generic [* * *] Product for human
use supplied to PAR (and its Affiliates) by GSK (and its Affiliates) pursuant to the provisions of this Agreement as further detailed in the specifications set forth in Schedule 4.2(b)(iii) to the Main Agreement for use in humans 

"Territory" 
 Territory shall mean the United States of America (including
the Commonwealth of Puerto Rico) its possessions and territories and U.S. military and/or government installations that are under the purview of the FDA. 
  

	3.	Responsibilities 

 PAR will notify GSK (with such notice made to the
appropriate contact listed in Attachment 1) of all information (initial or follow-up) coming into its possession concerning AE or pregnancy reports associated with commercial or clinical uses, studies, investigations or tests with Product, in the
Territory, whether or not determined to be attributable to Product. PAR will transmit such AE and pregnancy reports to GSK so that they are received by GSK within one (1) business day after receipt by PAR. 
 PAR will inform those who report AEs or pregnancies that the information provided to PAR will be forwarded to the manufacturer for appropriate follow-up. 
 GSK will be responsible for submitting AE and pregnancy reports regarding Product to the applicable authorities or agencies. 
 PAR will train their staff who will be managing reports regarding Product to ensure they have basic knowledge of AE and pregnancy reports and AE-related procedures.

  

	4.	Means of Notification 

 The preferable method of notification to GSK
is via encrypted e-mail (with pdf attachments if necessary) using receipt acknowledgement. Alternatively, notification to GSK may be via fax transmission. 

 Pursuant to 17 CFR 240.24b-2, confidential information has been omitted in places marked “[*
* *]” and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application filed with the Commission. 
  

 Date of first receipt by PAR of any AE or pregnancy report must be recorded on each report sent. This includes
initial and all follow-up receipt dates. 
  

	5.	Termination of the Pharmacovigilance Agreement 

 If the Product
subject to this Agreement is subsequently divested or discontinued, or the overall Main Agreement between GSK and PAR is terminated, this Agreement will be terminated promptly. Assignability of this Agreement is to the same extent as the Main
Agreement. 
  

	6.	Signed 

  

			
	[insert GSK signatory/title]	  	[insert PAR signatory/title]
	[insert GSK dept.]	  	[insert PAR dept.]
	[insert GSK address]	  	[insert PAR address]

  

			
	 Signed
	  	Signed
		
	 Date
	  	Date

 Pursuant to 17 CFR 240.24b-2, confidential information has been omitted in places marked “[*
* *]” and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application filed with the Commission. 
  

 Attachment 1: Contacts 
 For GlaxoSmithKline 
  

					
	Receiving AE and pregnancy reports	  	 [***]
	  	 [***]
  
 Global Clinical Safety and Pharmacovigilance
  
 GlaxoSmithKline R&D
  
 Five Moore Drive
  
 P.O. Box 13398
  
 Research Triangle Park, NC 27709-3398

 For PAR 
  

					
	Enquiries regarding AE and pregnancy reports	  	Name	  	 Address and tel/fax numbers:
  
 E-mail address

 Pursuant to 17 CFR 240.24b-2, confidential information has been omitted in places marked “[*
* *]” and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application filed with the Commission. 
  

 SCHEDULE 6.3 
 Press Release 
 [PAR to provide draft for GSK review]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00119-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00119-of-00352.parquet"}]]